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Abstract 
 
 Excessive microvascular permeability is a serious complication involved in 
traumatic injury and inflammatory diseases. Alcohol intoxication can exacerbate the physiological 
derangements produced by microvascular endothelial barrier dysfunction in such disease 
conditions. Sphingosine-1-phosphate (S1P) has known endothelial barrier-protective properties, 
and has been shown to ameliorate microvascular leakage in a model of combined alcohol 
intoxication and hemorrhagic shock and resuscitation (HSR). However, whether the barrier-
protective properties of S1P extend to endothelial cells of the blood-brain barrier (BBB) is unclear. 
The mechanisms of S1P-induced barrier protection during alcohol intoxication or HSR are also 
unknown. In the current study, we tested the hypothesis that S1P could enhance endothelial 
barrier during alcohol intoxication or hemorrhagic shock by preserving the integrity of junction 
proteins and the endothelial glycocalyx, and protecting mitochondrial function.  
Cultured primary human brain microvascular endothelial cell (HBMEC) monolayers were 
used to characterize endothelial-specific mechanisms of S1P protection of the BBB during alcohol 
treatment.  Transendothelial electrical resistance (TER) and apparent permeability coefficients for 
albumin, dextran-4 kDa, and sodium fluorescein were used as indices of barrier function. 
Junctional localization was determined by immunofluorescence confocal microscopy. We also 
used an established in vivo rat model of conscious HSR and assessed microvascular leakage, 
endothelial glycocalyx integrity, and mitochondrial function by intravital microscopy. Cultured rat 
intestinal microvascular endothelial cell (RIMEC) monolayers were used to test the ability of S1P 
to protect against glycocalyx shedding and endothelial barrier dysfunction caused by direct 
disruption of mitochondrial integrity due to inhibition of mitochondrial complex III. The results show 
 vii 
that alcohol significantly impaired HBMEC TER and increased solute permeability, which was 
reversed with application of S1P after alcohol treatment. Alcohol caused the formation of gaps 
between cells. Treatment with S1P (after alcohol) increased junctional localization. Our in vivo 
results show that S1P protects against HSR-induced hyperpermeability, preserves the expression 
of adherens junctional proteins, and protects against glycocalyx degradation. S1P treatment 
during HSR also protects against mitochondrial membrane depolarization. Besides that, S1P 
protects RIMECs against mitochondrial dysfunction-induced endothelial barrier dysfunction and 
glycocalyx degradation by acting through mitochondrial complex III. 
Our results indicate that S1P may be useful for restoring BBB function during alcohol 
intoxication. Moreover, S1P protects against HSR-induced mitochondrial dysfunction in 
endothelial cells, which in turn improves the structure of the endothelial glycocalyx after HSR and 
allows for better junctional integrity to prevention of excess microvascular permeability. 
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Chapter One: 
Introduction – Endothelial Barrier Function 
 
1.1 Overview of Endothelial Barrier Function 
The microcirculation is essential to the function of the cardiovascular system. It is at the 
level of the microcirculation where the exchange of fluids, solutes and inflammatory cells between 
blood and tissue occurs [1]. The components of the microcirculation are arterioles, capillaries and 
venules. Together, these microvessels contribute to the control of blood pressure, distribution of 
blood throughout the body, and localized tissue perfusion [2]. Capillaries and post-capillary 
venules are the major site of blood-tissue exchange, and are important sites of inflammation [3]. 
A barrier composed of endothelial cells, endothelial glycocalyx, basement membrane and some 
accessory cells such as smooth muscle cells and pericytes, tightly controls the permeability of the 
microcirculation to fluids and solutes. Under physiological conditions, water, ions, and small 
molecules such as glucose are more likely to cross the endothelium by passing in between cells 
(paracellular transport), while larger molecules are more likely to cross the endothelium through 
active transport mechanisms, i.e. the transcellular pathway mediated by caveolae and vesiculo-
vacuolar organelles [4,5]. Several pathophysiological conditions, such as trauma, ischemia-
reperfusion injury, sepsis, diabetes, and cancer are characterized by increased microvascular 
permeability due to underlying changes in the structural conformation of endothelial cells. Such 
conformational changes are caused by inflammatory mediators such as histamine, platelet 
activating factor and cytokines. The resulting increase in microvascular permeability to fluids and 
plasma proteins causes edema formation [6]. If the exacerbated fluid loss in the onset of these 
diseases is not promptly controlled, an extended and aggravated inflammatory response can lead 
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to further tissue injury and eventual organ failure [2]. Therefore, finding strategies to minimize 
microvascular hyperpermeability during such inflammatory conditions may prevent or reduce 
edema-related complications and improve patient outcome. An effective approach to improve 
barrier function may also have application in multiple pathological conditions, given that many of 
them involve disruption of the endothelial barrier and microvascular leakage. 
 
1.2 Determinants of Endothelial Barrier 
 
1.2a Adherens Junctional Proteins and Endothelial Barrier  
Under physiological conditions, hydrostatic and diffusional gradients drive the transport of 
water and solutes through the junctional clefts between endothelial cells. This paracellular 
pathway contains a fibrous matrix of proteins that can select and exclude solutes from ions to 
macromolecules based on their size and charge [6-8]. Inflammatory and pathophysiological 
conditions lead to opening of this paracellular pathway, increasing the permeability of the 
microvasculature to plasma proteins, and facilitating the transendothelial passage of inflammatory 
cells, pathogens and even metastatic tumor cells [9,10]. Integrity of the structural proteins that 
compose the junctional cleft is crucial for proper endothelial barrier function. These proteins 
control paracellular permeability by conferring cell-cell adhesion and barrier “tightness.” There are 
multiple families of junctional proteins present in the paracellular cleft of the microvascular 
endothelium: tight junctions (TJ), adherens junctions (AJ), gap junctions (connexons), and 
desmosomal complexes. TJ and AJ proteins have been of particular interest to the field, and are 
ubiquitously expressed along various vascular beds. However, there is variability in expression 
within specialized microvascular beds; for example TJ proteins are more prominently expressed 
in the microvasculature of the blood-brain barrier [11].  
It is currently thought that AJ proteins play a major role in controlling the endothelial barrier 
in the microvasculature. Data from studies have shown that systemic microvascular permeability 
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is achieved by selectively disrupting the normal junctional organization of the protein vascular 
endothelial cadherin, or VE-cadherin, the major component of the AJs [12-14]. The VE-cadherin 
has intracellular and extracellular domains, spanning the plasma membrane. The extracellular 
domain of one VE-cadherin molecule in one cell forms calcium-dependent homotypic bonds with 
the extracellular domain of a VE-cadherin expressed in the membrane of an adjacent endothelial 
cell, limiting the passage of fluids and solutes from through the junctional clefts [15,16]. The 
mechanisms that regulate VE-cadherin expression at the junctions are of major importance for 
controlling microvascular permeability and leukocyte extravasation [17]. The intracellular domain 
of VE-cadherin connects to the actin cytoskeleton by linking to the catenin family of proteins [5], 
of which -catenin is of interest in this dissertation. Dissociation of the VE-cadherin/β-catenin 
complex leads to increased microvascular permeability [18]. Other adhesion molecules such as 
E-cadherin, junctional adhesion molecules (JAM) and platelet-endothelial cell adhesion 
molecules (PECAM-1) are also present at the paracellular cleft [2]. However, their contribution to 
endothelial barrier function is not well understood. It is worth highlighting, however, that PECAM-
1 is known to play a role in the development of inflammation by binding to integrins on leukocytes 
and facilitating their transmigration across the vascular endothelium [2].  
The TJ proteins have similar structures to the adherens junctions, but their role in 
enhancing endothelial barrier integrity is thought to be more important for the blood-brain and 
blood-retinal barriers [19]. These proteins have transmembrane domains and their extracellular 
domains bind homotypically with the extracellular domains of tight junction molecules on 
neighboring endothelial cells. They include claudins, occludins and JAM-A. On the cytoplasmic 
side, they connect to the actin cytoskeleton via the zona occludin-1 proteins (ZO-1). Besides 
playing a role in the structure of the paracellular cleft, ZO-1 proteins have been shown to serve 
as signaling molecules to enhance tight junctions [20]. Together, TJs and AJs are essential for 
the functional integrity of the endothelial barrier and changes in their structure can modulate 
microvascular permeability. 
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1.2b The Endothelial Glycocalyx and Endothelial Barrier  
The endothelial glycocalyx layer has also been demonstrated to be an important 
modulator of microvascular permeability [21,22]. The glycocalyx is a multilayer structure that 
covers the surface of endothelial cells and interacts with plasma proteins and lipids [23,24]. It is 
composed of proteoglycans, glycoproteins, and glycolipids that are associated with the 
endothelial cell membrane and bind extracellularly to oligosaccharide side chains such as 
Heparan Sulfate and Chondroitin Sulfate. Even though the glycocalyx layer is ubiquitously 
expressed in the circulatory system, its composition and thickness fluctuates throughout the 
vasculature [25]. In the rat mesenteric microcirculation, which is the microvascular bed we 
primarily studied, the glycocalyx is unevenly distributed, while it is more uniformly distributed in 
rat aorta [26]. The variations in glycocalyx thickness could be associated with different vessel 
permeability properties [27]. The glycocalyx has a net negative charge, protecting endothelial 
cells from negatively charged molecules, and repelling red and white blood cells (leukokcytes) 
[28]. In addition, molecules larger than 70 kDa are excluded from the glycocalyx. Albumin, which 
is 67 kDa and has a negative net charge, is able to bind tightly to the glycocalyx due to its 
amphoteric nature, reducing the hydraulic conductivity across the vascular barrier [29]. The 
glycoproteins that compose the glycocalyx also act as adhesion molecules for plasma 
constituents to bind to endothelial cells. They express immunoglobulins including intercellular 
adhesion molecules 1 and 2 (ICAM-1 and -2) that act as ligands for integrins on the surface of 
leukocytes and platelets, mediating their adhesion to the endothelium. Therefore, the endothelial 
glycocalyx layer plays a role not only in the homeostasis of the vascular system, but also in 
protecting the vasculature from circulating inflammatory cells and pathogens. 
The endothelial glycocalyx is one of the first components of the endothelial barrier to be 
involved in barrier dysfunction during inflammation. Damage to the glycocalyx can lead to 
microvascular permeability and edema [25]. For example, enzymatic degradation of the 
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glycocalyx in rat myocardial capillaries causes myocardial edema [30]. During acute inflammatory 
responses, disruption of the glycocalyx exposes endothelial cells to leukocyte adhesion, 
exacerbating the inflammation. Exposure to inflammatory factors such as tumor necrosis factor 
alpha (TNF-α) and bacterial lipopolysaccharide have also been shown to degrade the glycocalyx 
[29,31]. Ischemia-reperfusion injury also nearly completely degrades the glycocalyx layer by 
generating oxygen free radicals [32].  
Studying how different challenges affect the glycocalyx and paracellular junctional 
proteins may have a positive impact in the development of new strategies to improve endothelial 
barrier function during pathophysiological conditions. To this end, some interventions to prevent 
or repair glycocalyx damage during injury have been proposed. For example, maintaining the 
physiological concentrations of plasma proteins, particularly albumin, has been demonstrated to 
be quite effective [33]. However, the mechanisms of glycocalyx protection and its interaction with 
paracellular junctional proteins to maintain endothelial barrier function have been understudied. 
 
1.3 S1P and Endothelial Barrier 
 Sphingosine-1-phosphate (S1P) is a blood-borne bioactive lipid. S1P is synthesized by 
red blood cells and platelets [34], and in the circulation it is largely bound to high-density 
lipoproteins (HDL) and albumin for systemic distribution [35]. Its plasma concentration can vary 
depending on the context, and is typically found between 10 nM to 4 µM [36]. S1P contributes to 
a variety of physiological functions, which are attributable to its binding to G-protein-coupled 
receptors on the cell membrane and to intracellular receptors [37,38]. The receptor-mediated 
effects of S1P have been studied in a variety of cell types. Endothelial cells have been 
demonstrated to express S1P receptors 1, 2 and 3 (S1PR1, S1PR2, and S1PR3, respectively), 
which together regulate endothelial cell functions associated to vascular development, tone and 
permeability [39-41]. 
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 In contrast to work done in endothelial cells in vitro, the protective effects of S1P on 
permeability and barrier function have not as widely been studied in vivo. One study reported that 
intravenous injection of S1P reduces edema formation and inflammation in a murine lung model 
of LPS-induced acute lung injury (ALI) [42]. The same study shows that FTY720, a S1P analogue 
that is used for the treatment of multiple sclerosis, also decreases LPS-induce microvascular 
leakage. A canine model of ALI showed that infusion of S1P reduces protein accumulation and 
edema formation after intrabronchial LPA administration [43]. Our lab has also recently 
demonstrated the potential of S1P to attenuate endothelial barrier dysfunction in a rat model of 
acute alcohol intoxication and hemorrhagic shock and resuscitation [44]. These exciting results 
from in vivo models of hyperpermeability show the potential of S1P in the treatment of 
microvascular barrier dysfunction. However, further investigation is needed to elucidate the 
mechanisms of S1P-mediated barrier protection. 
 
1.4 Gap in Knowledge and Objective of the Dissertation 
 As we have seen, traumatic injury and inflammatory diseases can lead to microvascular 
hyperpermeability, edema, organ failure, and death. Degradation of junctional proteins and the 
endothelial glycocalyx layer have been shown to be involved in such complications. Even though 
efforts have been made to understand the mechanisms underlying barrier dysfunction, there is a 
lack of effective therapeutic interventions and the morbidity is still high. S1P is a powerful barrier 
enhancer, however it is not known how the signaling mechanisms activated by S1P can be 
targeted to enhance barrier function during diseases that involve endothelium breakdown and 
vascular leakage.   
Our lab has successfully demonstrated that S1P protects endothelial barrier function in a 
combined model of acute alcohol intoxication (AAI) and hemorrhagic shock and resuscitation 
(HSR). In that study, we investigated whether the administration of different concentrations of S1P 
(0.003, 0.03 and 0.1 mg/kg) could limit microvascular hyperpermeability in rat mesenteric 
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microvessels. Our results demonstrated that the 0.1 mg/kg concentration effectively rescued 
albumin extravasation following AAI + HSR [44]. However, the effects of S1P on the structure of 
endothelial barrier and the mechanisms of S1P-mediated protection were not assessed. 
Therefore, the objective of this study was to investigate how different challenges affect the 
components of the endothelial barrier and to elucidate the potential mechanisms of S1P-induced 
barrier protection during such challenges. We used two different insults that are known to disrupt 
barrier function to pursue our objective. The first method was the treatment of brain microvascular 
endothelial cells with alcohol in vitro, and the second method was an in vivo model of HSR. We 
used these two models of endothelial barrier dysfunction to test the protective effects of S1P on 
paracellular junctions, glycocalyx health, and cell viability. 
We focused on this gap of knowledge and generated the central hypothesis that “S1P 
enhances endothelial barrier during alcohol intoxication or hemorrhagic shock by preserving the 
integrity of junction proteins and the endothelial glycocalyx, and protecting mitochondrial function”. 
We tested our hypothesis by executing three specific aims: Aim 1 was to determine whether S1P 
protects brain endothelial cells from alcohol-induced barrier disruption. Aim 2 investigated the 
effects of S1P on endothelial structural components following HSR. Lastly, Aim 3 was to 
determine whether S1P protects against mitochondrial dysfunction-induced endothelial barrier 
disruption. We designed our study to provide foundational knowledge for the development of 
therapeutic interventions for hyperpermeability-related disease conditions. Figure 1 summarizes 
the three specific aims in a conceptual figure.  
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Figure 1. Schematic Graph of two Adjacent Endothelial Cells and Specific Aims. 
A. Aim (1) investigates whether S1P protects brain endothelial cells against alcohol (EtOH)-
induced endothelial hyperpermeability and junctional disruption. B. Aim (2) investigates the 
effects of S1P in the endothelium structural components (junctions and glycocalyx) following HSR. 
Aim (3) investigates whether S1P protects mitochondrial function following HSR, and whether 
mitochondrial dysfunction can lead to junction and glycocalyx disruption. 
 
  
A 
B 
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Chapter Two: 
S1P Protects Brain Endothelial Cells Against Alcohol-induced Hyperpermeability and 
Junctional Disorganization  
 
2.1 Introduction 
 The blood-brain barrier (BBB) performs an important role in maintaining homeostasis in 
the central nervous system. This selectively permeable layer is composed of endothelial cells that 
protect the brain from blood-borne cytotoxins and regulate the entrance of molecules, while also 
ensuring the supply of nutrients for proper neural function. Brain microvascular endothelial cells 
are reported to have tighter intercellular junctions than peripheral endothelial cells [45]. Claudin-
5 and Occludin are the major tight junction proteins, which are highly expressed in brain 
endothelium [46]. Endothelial cells in the BBB also express vascular-endothelial cadherin (VE-
cadherin), bound to the cytoskeleton via β-catenin. Translocation of β-catenin to the nucleus has 
been shown to mediate transcriptional repression of claudin-5 in brain microvascular endothelial 
cells [47]. The functional integrity and low permeability of the BBB depends in part on high levels 
of expression of junctional proteins, and their high degree of localization at the junctional clefts 
[48]. Disruption of these proteins by disease or certain drugs may result in increased BBB 
permeability, exposing the brain to cytotoxins and inflammatory mediators, and consequently 
impairing neural function [47]. Hence, understanding how various factors can affect BBB 
junctional proteins is critical for improving methods for prevention of neurological diseases and 
for the development of novel treatments. 
Alcohol intoxication not only impairs brain function, but also results in neuroinflammation 
and neurodegeneration in humans and animals [49]. The mechanisms involved in alcohol-induced 
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pathologies include cellular changes, inflammasome activation, apoptosis, and reactive oxygen 
species (ROS) production [50]. Haorah et al. (2005) showed that alcohol causes disruption of 
brain endothelial cell monolayers, accompanied by decreased expression of ZO-1, claudin-5 and 
occludin [51]. Despite these advances in understanding, no strategies to improve BBB function 
under such conditions have been developed.  
 S1P is an abundant sphingolipid present in plasma at nanomolar to micromolar 
concentrations [52], and has been shown to enhance endothelial barrier function by inducing 
cytoskeletal, junctional and adhesion changes [53-55]. In the first part of this dissertation, we 
investigated the potential of S1P to enhance the barrier function of brain microvascular endothelial 
cell monolayers in the presence of alcohol. We assessed to what extent alcohol impairs barrier 
function and we hypothesized that S1P could ameliorate barrier dysfunction and junctional protein 
disruption caused by alcohol treatment. 
 
2.2 Materials and Methods 
 
2.2a Endothelial Cell Culture 
 Human Brain Microvascular Endothelial Cells (HBMEC) were used as an in vitro BBB 
model. Cells were obtained from ScienCell Research Laboratories (Carlsbad, CA) and grown in 
10 cm petri dishes in endothelial cell medium (ECM; ScienCell) supplemented with fetal bovine 
serum, endothelial growth supplement and penicillin/streptomycin (ScienCell), on 1.5% porcine 
gelatin matrix (Sigma-Aldrich, St. Louis, MO), in an incubator at 37 °C and 5% CO2. HBMECs 
were used at passages 1 to 3. 
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2.2b Pharmacological Agents 
 Ethyl alcohol was obtained from Pharmco by Greenfield Global (Shelbyville, KY), 
sphingosine-1-phosphate (S1P) was from Tocris Biotechne (Minneapolis, MN), and 8-CPT-2'-O-
me-cAMP-2’-O-Me-cAMP (8-CPT) was purchased from Merck-Millipore (Billerica, MA).  
2.2c in vitro Assessment of Endothelial Barrier Function 
 We assessed endothelial barrier function using two distinct methods. The first was to 
determine transendothelial electrical resistance (TER) of confluent cell monolayers using the 
Electric Cell-Substrate Impedance Sensing (ECIS) system (Applied Biophysics, Troy, NY) as 
previously described [56,57]. ECIS is a well-established indicator of endothelial barrier function 
based on the tightness of cell-cell junctions [20,58,59]. The advantages of this method are its 
sensitivity to detect small changes in barrier function due to nanometer-scale changes in the 
junctions between cells, and the ability to make moment-to-moment measurements, typically 
every 1-10 seconds apart [59]. Cells were subcultured onto gelatin-coated gold electrode arrays 
and allowed to grow at 37 °C for 3 - 5 days post-confluence before experiments to allow for 
maturation of paracellular junctions, with medium changed every other day. On the day of the 
experiment, the medium was changed to basal endothelial cell medium (bECM) 1 h before the 
start of the experiment, and the arrays were attached to the ECIS system. A 1 μA AC signal at 4 
kHz was applied through a 1-MΩ resistor to a constant-current source, and the in-phase and out-
of-phase voltage, respectively proportional to resistance and capacitance, were recorded with the 
ECIS software. The data are expressed as TER normalized to the 0-min time-point. Treatment 
was added at time = 0, followed by addition of S1P (1 µM) or vehicle. The ECIS system allows 
cells to be treated while simultaneously recording TER. 
 
 The second method we used to evaluate barrier function was to determine the apparent 
solute permeability (Psolute) of HBMEC monolayers to molecules of different sizes, as previously 
described [57,60,61]. Briefly, HBMEC were seeded on the upper chamber of gelatin-coated 
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Transwell membranes (0.4 µm; Corning, Corning, MA), and allowed to grow until 3 days post-
confluence so that they formed mature junctions. On the day of the experiment, the medium was 
changed to ECM. After 1 hour of baseline, a stock concentration of the molecular tracers sodium 
fluorescein (0.4 kDa) or sodium fluorescein isothiocyanate (FITC)-conjugated to albumin (66.4 
kDa) or dextran (4 kDa) was added to the upper chamber. HBMECs were immediately treated 
with vehicle + vehicle (0.1% BSA in PBS), alcohol + vehicle, or alcohol + S1P. The S1P was 
added 5 minutes after alcohol treatment. After 60 minutes of total treatment, samples of media 
were collected from both upper (luminal) and lower (abluminal) chambers for fluorometric 
analysis. For the sodium fluorescein tracer, the samples were collected after 10 minutes of alcohol 
treatment, to avoid equilibration of this tracer in both chambers, which happens within less than 
an hour. The concentration of the tracer in each chamber was determined using a standard curve, 
and the permeability coefficient was calculated using the equation Psolute = [(CA/t) x (1/A) x (V/CL)], 
where CA is the abluminal concentration, t is the time (in seconds), A is the area of the membrane 
(in cm2), V is the volume of the abluminal chamber, and CL is the luminal concentration. 
 
2.2d Experimental Protocols 
 To assess whether alcohol causes concentration-related changes in TER, the cells were 
treated with 50, 75 or 100 mM ethyl alcohol. These concentrations are equivalent to two to three 
times the legal limit for blood alcohol concentration in the United States. The alcohol was diluted 
in 0.1% BSA dissolved in PBS (vehicle) prior to addition to the cell media. Controls were treated 
with isovolumic vehicle. To assess the effects of the barrier enhancers, cells were treated with 
either S1P (1 μM), 8-CPT (100 μM), or isovolumic vehicle (0.1% BSA in PBS). To test whether 
S1P could reverse any effects of alcohol, cells were treated with alcohol, followed by 1 μM S1P 
or isovolumic vehicle, which were administered 5 minutes after alcohol treatment. 100 μM 8-CPT 
, a well-studied endothelial barrier enhancer, was used as a positive control for barrier 
enhancement. It is worth noting that for S1P, the barrier-protective properties occur at 
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physiological concentrations (0.1-1.0 μM). At higher concentrations (10 μM), S1P significantly can 
impair barrier function by disrupting ZO-1 structure and the distribution of F-actin in endothelial 
cells [62]. Therefore, the concentrations of S1P and 8-CPT used in this study were based on the 
effective concentrations for enhancing barrier function as previously reported [63,64].  
 
2.2e Immunofluorescence Labeling and Laser Confocal Microscopy 
 To assess the impact of alcohol on intercellular junctions and the potential of S1P to 
restore junctional integrity, cultured brain endothelial cells were immunolabeled for VE-cadherin 
(C-19, Santa Cruz Biotechnology, Santa Cruz, CA), Claudin-5 (4C3C2, Invitrogen) and β-catenin 
(L54E2, Cell signaling) following treatment with vehicle + vehicle (0.1% BSA in PBS), alcohol + 
vehicle, or alcohol + S1P. S1P was added 5 minutes after the treatment with alcohol. The cells 
were fixed for immunofluorescence labeling 15 minutes after alcohol was added, to match the 
time-point of maximum drop in TER caused by alcohol, as observed in the ECIS assay. Briefly, 
HBMEC were seeded onto gelatin-coated glass coverslips (Fisher Scientific, Hampton, NH) and 
incubated in endothelial growth medium until confluent. The medium was changed to bECM and 
allowed to incubate for 1 hour before the treatment. After the various treatments, cells were fixed 
in 4% paraformaldehyde in PBS for 10 minutes, permeabilized in 0.1% Triton-X-100 in PBS for 
10 minutes and blocked for nonspecific binding with 10% serum in PBS for 30 minutes. Cells were 
incubated with primary antibodies overnight at 4 °C. They were then washed 3X for 10 minutes 
with 0.1% Tween-20 in PBS, followed by incubation for 1 hour with Alexa 488- and Alexa-555-
conjugated secondary antibodies (Life Technologies, Carlsbad, CA). The samples were washed 
3X again and the coverslips were mounted onto microscope slides with Vectashield containing 
DAPI (Vector Laboratories, Burlingame, CA). Images were collected with an Olympus FV1200 
spectral inverted laser scanning confocal microscope (Olympus, Center Valley, PA), and the 
images were analyzed with NIH ImageJ software [65]. 
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2.2f Data Analysis  
 For time-course data, the tracings show mean normalized TER over time for each 
experimental group. Other summarized data are presented as the mean ± SE. 
Immunofluorescence confocal images were analyzed using ImageJ software. Junction protein 
expression is given as the integrated optical intensity (IOI) of regions of interest (ROI) created on 
the borders of endothelial cells. Values of N are for the number of cell assays, representing 
independent experiments, unless otherwise stated. Differences between two groups were 
assessed using unpaired t-tests. When three or more groups were compared, analysis of variance 
(ANOVA), and when appropriate, post-hoc tests to compare treatment groups to the control 
(Dunnett’s test) or to compare all groups (Tukey’s test) were performed. For the permeability 
coefficient analysis, a two-way ANOVA was performed with the treatments (control, alcohol, and 
alcohol+S1P) and solutes (fluorescein, dextran-4kDa, and albumin) as factors, and Holm-Sidak 
multiple comparisons test used for post-hoc analysis. Significance was accepted when P < 0.05. 
 
2.3 Results 
 
2.3a Alcohol Elicits Barrier Dysfunction of Brain Endothelial Cell Monolayers. 
 The direct impact of different alcohol concentrations (50, 75, and 100 mM) on barrier 
function of human brain microvascular endothelial cell monolayers was assessed using ECIS. 
Consistent with a previous study on the effects of alcohol on BBB function [66], we found that 
alcohol causes a concentration-related decrease in HBMEC barrier function (Fig. 2). Alcohol 
applied at 75 mM and 100 mM alcohol significantly decreased TER compared to vehicle (0.1% 
BSA in PBS) control (Fig. 2B). The maximum drop in TER was within the first 15 minutes of 
treatment, and was followed by a sustained decrease in TER compared to baseline that lasted 
for over 2 hours (Fig. 2A). 
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2.3b S1P Rescues Alcohol-induced Barrier Dysfunction on Brain Endothelial Cells. 
 Next, we tested whether S1P’s barrier-enhancing properties extend to HBMEC 
monolayers. S1P increased TER to 38% above baseline on average (Fig. 3A), while the positive 
control 8-CPT caused an average 28% increase (Fig. 3C). Vehicle controls caused no change in 
TER. To examine whether S1P could rapidly restore barrier dysfunction caused by alcohol 
treatment, we first treated HBMEC monolayers with 75 mM alcohol to elicit a drop in TER, and 
added S1P 5 minutes later. S1P restored TER well above baseline levels (Fig. 3E). This response 
was quite rapid, and significantly reduced the amount of the time needed for TER to recover to at 
least baseline levels after the addition of alcohol (Fig. 3F). Treatment with 8-CPT also ameliorated 
alcohol-induced barrier dysfunction and decreased the time of recovery, compared to alcohol 
alone (Fig. 2G, H). These data indicate that S1P’s barrier enhancing properties apply to brain 
endothelium, and that S1P has the potential to protect barrier function in the presence of alcohol.  
 
2.3c S1P Rescues Alcohol-Induced Increases in Endothelial Permeability. 
 While TER is an indicator of endothelial cell-cell “tightness”, it does not necessarily 
represent permeability to plasma proteins or other solutes. Therefore, we also determined how 
alcohol impacts permeability coefficients of HBMEC monolayers to molecules of three different 
sizes: sodium fluorescein (0.4 kDa), FITC-dextran (4 kDa) and FITC-albumin (66.4 kDa). Three 
groups were compared (control, alcohol, and alcohol + S1P), and two-way ANOVA revealed a 
significant difference due to these treatment groups, independent of which tracer was used 
(p<0.001). Post-hoc analysis of the main treatment groups revealed that alcohol treatment 
significantly increased permeability compared to control, and that addition of S1P in the presence 
of alcohol significantly decreased permeability compared to alcohol alone (Fig. 4). It is worth 
noting that when a similar post-hoc analysis was performed with subgroups for each individual 
tracer, no significant differences were found, likely due to the smaller sample sizes in each 
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subgroup. These data suggest that alcohol can increase the permeability of brain endothelial cells 
monolayers, and that S1P has the potential to decrease permeability in the presence of alcohol. 
 
2.3d S1P Enhances Paracellular Junction Protein Localization in the Presence of Alcohol. 
 To assess whether the alcohol-induced decrease in barrier integrity may be due to the 
disruption of junctional protein organization, we investigated the localization of Claudin-5, VE-
cadherin, and β-catenin (Fig. 5). We also tested the ability of S1P treatment (5 min. after addition 
of alcohol) to rescue any changes caused by alcohol. In control HBMEC monolayers, claudin-5, 
VE-cadherin and β-catenin form a continuous border between cells, with junctions that appear 
very tight. We observed that treatment with 75 mM alcohol for 15 minutes caused an apparent 
disruption on the normal junctional integrity of all three proteins. In many cells treated with alcohol, 
instead of the typical continuous junctional protein belt between cells, there was an apparent shift 
of the proteins to the cytoplasm. We also found that treatment with alcohol caused formation of 
gaps between HBMECs. In contrast, when S1P was added to alcohol-treated cells, these effects 
appeared to be reversed. To quantify our observations, we evaluated content of these proteins at 
the paracellular junctions by measuring the intensities of the immunofluorescence labeling with 
regions of interests drawn at cell borders. Alcohol treatment did not cause a significant change in 
junctional content of Claudin-5, VE-cadherin, and β-catenin. However, addition of S1P after 
alcohol significantly elevated the intensities of all three when compared to the cells treated with 
alcohol alone (Fig. 5). These data suggest that the ability of alcohol to reduce barrier function and 
cause junctional gaps does not necessarily involve a significant loss of VE-cadherin, claudin-5, 
and -catenin at intercellular junctions. However, the enhanced barrier function elicited by S1P 
appears to involve increasing or stabilizing the amounts of VE-cadherin, Claudin-5, and -catenin 
within intercellular junctions.  
2.4 Discussion 
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 Exogenous S1P has been shown to enhance endothelial barrier function at physiological 
concentrations, while prolonged or high-dose supplementation with S1P can reverse these 
beneficial effects [62,67]. Previous studies have typically shown a rapid and brief response 
caused by low-dose S1P treatment in HUVEC, significantly increasing the TER within 2 min, 
followed by a peak at 5 min, and a decline by 10 min [62,68]. The current results extend the 
barrier-protective effects of S1P to HBMEC, and show some similarities with these previous 
results. For example, TER also starts to decrease 10 min after S1P treatment, although our data 
show that S1P-induced enhancement of barrier function is sustained above baseline levels for at 
least 60 minutes in HBMEC monolayers (Fig. 3A). 
 The key finding in this study is that S1P can improve the integrity of HBMEC monolayers 
that have been exposed to alcohol-induced stress. We first demonstrated that alcohol disrupts 
barrier function in this model of the BBB, as evidenced by the drop in TER on HBMEC monolayers 
(Fig. 2). We also showed that S1P treatment, at a physiological concentration, reversed the 
effects of alcohol by significantly decreasing the time needed for recovery to baseline TER in 
alcohol-treated brain endothelial cell monolayers (Fig. 3E, F). We found that these findings extend 
to solute permeability (Fig. 4). Furthermore, we observed that alcohol causes a displacement of 
junctional proteins from the cell borders to the cytoplasm, and causes gap formation between 
endothelial cells. S1P significantly reverses the effects of alcohol by recruiting these proteins back 
to the cell borders, significantly increasing their junctional content and reinforcing a tight 
endothelial monolayer (Fig. 5). A possible explanation for the increase in interendothelial 
junctional proteins above baseline levels after S1P treatment is that S1P recruits all the available 
Claudin-5, -catenin, and VE-cadherin to the cell periphery, including protein molecules that were 
not yet localized to the cell border before alcohol treatment. This experimental evidence supports 
the overall concept that exogenous S1P has potential to protect barrier function of brain 
microvessels during alcohol intoxication. 
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 An important limitation of this study is that our model of the BBB utilized only HBMEC and 
not additional supporting cells that would be found in the brain. While this model enabled us to 
examine the direct impact of alcohol and S1P on brain endothelial cells, we would expect a tighter 
BBB in vivo. The observation that alcohol rapidly reduces TER of HBMEC and increases the 
permeability might not be relevant in the healthy brain, but is likely to be relevant in a “double-hit” 
scenario, such as when an injury occurs during alcohol intoxication, or if a chronic 
neuroinflammatory disease is already present, amplifying the overall detrimental challenge faced 
by the brain endothelial cells. In such situations, the BBB might become more permeable to larger 
molecules that typically do not enter the realm of the central nervous system in the presence of 
alcohol alone. We have observed this type of effect in the mesentery, in which alcohol intoxication 
exacerbates hemorrhagic shock and resuscitation-induced hypotension and mesenteric 
microvascular leakage in vivo [44]. Importantly, treatment with S1P can reverse these detrimental 
effects [44].  
 Based on these previous observations and the current findings, we conclude that there 
may be potential benefit of the use of S1P or activation of its receptors in conditions that involve 
alcohol-induced disruption of the BBB. We speculate that S1P-induced blood-brain barrier 
enhancement may also be useful for “two hit” scenarios, which represent a topic for future 
investigation. 
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Figure 2. Alcohol-induced endothelial barrier dysfunction in cultured human brain 
endothelial cell (HBMEC) monolayers. A. Traces from an individual experiment 
showing the time course of changes in transendothelial electrical resistance (TER) in 
HBMEC monolayers following application of vehicle (0.1% BSA in PBS) or 50, 75, or 100 
mM alcohol. B. The mean maximum alcohol-induced changes in TER in HBMEC, 
observed 5 minutes post-alcohol treatment were compared. *p<0.05, alcohol vs. vehicle 
control (one-way ANOVA, Dunnett’s multiple comparisons test). N = 4 experiments, 4 
monolayers for each concentration. 
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Figure 3. S1P restores TER in alcohol-treated human brain endothelial cell monolayers. A. 
Traces from an individual experiment showing the time course of changes in TER of HBMEC 
treated with 1 µM S1P. B. The bar graph represents the mean maximum % increase in TER in 
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HBMEC treated with 1 µM S1P, observed 10 minutes after addition of S1P. C. Time course of 
changes in TER of HBMEC treated with 100μM of the Epac Activator 8-CPT, used as a positive 
control. D. The bar graph represents the maximum % increase in TER in HBMEC monolayers 
treated with 100 μM 8-CPT, observed 15 minutes post-treatment. E. Traces from an individual 
experiment show the time-course change in TER of HBMEC monolayers treated with alcohol (75 
mM) followed by S1P (1 μM) or vehicle. Alcohol was added at the 0 min time point, and caused a 
drop in TER. S1P, added 5 minutes later, enhanced barrier function and restored TER in alcohol-
treated cells above baseline levels. F. Cells treated with S1P took significantly less time to recover 
back to baseline levels, compared to vehicle controls. G. Traces from an individual experiment 
show the time course change in TER of HBEMC treated with 75 mM alcohol followed by 100 μM 
8-CPT or vehicle (0.1% BSA in PBS). H. Cells treated with alcohol followed by vehicle took above 
150 minutes to recover TER to baseline levels. Cells treated with alcohol followed by 8-CPT took 
significantly less time. *P < 0.05 S1P/8-CPT vs. vehicle treated group (unpaired t-test). N = 5 - 6 
experiments each group. 
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Figure 4. Impact of alcohol treatment on HBMEC monolayer permeability. Monolayers were 
treated with vehicle + vehicle (0.1% BSA in PBS), 75 mM alcohol + vehicle, or 75 mM alcohol + 
1 µM S1P. Transwell permeability assays were performed to calculate the apparent permeability 
coefficients for FITC-albumin (66.4 kDa), FITC-dextran (4 kDa) and sodium (Na)-fluorescein (0.4 
kDa).  The permeability coefficents (Psolute) represent an average over 1 hour for FITC-albumin 
and FITC-dextran, while only a 10-min time period was used for sodium fluorescein due to its 
relatively high permeability. Two-way ANOVA analysis revealed a significant difference among 
the three treatment groups (p<0.001). *Indicates p<0.05 between the groups indicated in post-
hoc analysis (Holm-Sidak test multiple comparisons test, all solutes included). A similar post-hoc 
analysis with subgroups for each individual tracer was also performed and revealed no significant 
differences. N=3 independent experiments (with 4 replicates within each experiment) were 
performed for the sodium fluorescein and FITC-dextran-4 kDa groups, and N=4 experiments were 
performed for the FITC-albumin group. 
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Figure 5. Alcohol causes intercellular gap formation, while S1P enhances paracellular 
protein organization at intercellular junctions in the presence of alcohol.  
A. Representative confocal immunofluorescence microscopy z-projections of claudin-5 (green) 
and VE-Cadherin (red) in confluent cultured HBMEC treated with vehicle + vehicle (0.1% BSA in 
PBS), alcohol + vehicle, and alcohol + S1P. Arrows indicate gap formation associated with alcohol 
treatment. Cells treated with 75 mM alcohol followed by 1 μM S1P do not present gap formation. 
While the quantification (bar graphs) of VE-cadherin and claudin-5 at the paracellular cleft do not 
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show a significant change upon alcohol treatment, S1P treatment after alcohol significantly 
increases their localization at junctions compared to alcohol alone.  
B. Representative immunofluorescence microscopy images of β-catenin of confluent HBMEC 
monolayers treated with vehicle + vehicle, alcohol + vehicle, and alcohol + S1P. Arrows indicate 
gap formation associated with alcohol treatment. Treatment with S1P after alcohol was able to 
restore junctional integrity. Quantification of β-catenin at the paracellular junctions of HBMECs 
monolayers treated with vehicle + alcohol do not show a significant change compared to vehicle-
only treated cells. However, S1P treatment significantly increases β-catenin content at the 
junctions (bar graph). Cell nuclei are labeled in blue. Scale bar = 45 μm. Images were analyzed 
using ImageJ software, **P < 0.01, *P 0.05 alcohol + S1P vs. alcohol + vehicle (one-way ANOVA, 
with Tukey’s multiple comparisons test). N = 7 - 8 areas for each treatment group. 
 
  
 25 
 
 
 
 
 
Chapter Three: 
Administration of Exogenous S1P Ameliorates Hemorrhagic Shock and Resuscitation-
Induced Endothelial Structural Abnormalities and Microvascular Hyperpermeability 
 
3.1 Introduction 
 Increased microvascular permeability to plasma proteins is a hallmark of traumatic injuries 
and sepsis, and is involved in the pathophysiology of diabetes, ischemia-reperfusion, and, cancer 
[2,69]. Failure to control the excessive extravasation of fluids and proteins results in edema, 
impairing normal tissue homeostasis. Hemorrhagic shock involves significant loss of intravascular 
volume that decreases tissue perfusion and leads to systemic microvascular hyperpermeability 
[6]. If the extravasation of fluids is not readily resolved, the complications can progressively 
worsen and culminate in multiple organ failure, which accounts for 50-60% of trauma related 
deaths [70]. Fluid resuscitation following hemorrhage remains a major challenge, as initial 
resuscitation with standard care fluids may not improve patient outcome and may exacerbate 
endothelial damage [71,72].  
 Paracellular junctional proteins play a major role in controlling the endothelial barrier 
function in the microvasculature. VE-cadherin is an important adherens junctional protein that is 
connected to the actin cytoskeleton via association with catenins, particularly β-catenin [73]. 
Dissociation of the VE-cadherin/β-catenin complex leads to increased microvascular permeability 
[18,74]. Early studies on the effects of inflammatory mediators on barrier integrity suggested that 
increases in endothelial permeability are associated with changes in actin cytoskeleton 
organization and formation of paracellular gaps [75-77]. More recent studies using in vitro models 
of burn injury showed increased endothelial monolayer permeability and barrier disruption upon 
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treatment with plasma from mice that had suffered burn injury. This was associated with actin 
stress fiber formation, loss of VE-cadherin/β-catenin complex from the cell periphery and gap 
formation in the paracellular cleft [78,79]. In vivo studies using models of hemorrhagic shock have 
shown increased permeability of the microvasculature, suggesting disruption of junctional 
proteins [44,80]. 
 In addition to coordination between paracellular junctional proteins and the actin 
cytoskeleton, the endothelial glycocalyx layer (EGL) has also been elegantly demonstrated to be 
a modulator of microvascular permeability and immune cell-vessel wall interactions [81]. 
Shedding of glycocalyx components has been shown in both small and large animal models of 
hemorrhagic shock [82-85]. Moreover, severely injured trauma patients display glycocalyx 
degradation in association with increased microvascular permeability [86]. Studies aimed at 
diminishing microvascular permeability following hemorrhage suggest the involvement of plasma 
components in glycocalyx health. For example, one study compared the in vivo effects of 
resuscitation with normal saline, lactated Ringer’s, 5 % albumin or fresh frozen plasma (FFP), 
focusing on maintenance of the endothelial glycocalyx and microvascular barrier integrity after 
hemorrhagic shock. The outcome was that the crystalloids failed to protect against shedding and 
thinning of the glycocalyx, increased permeability, and leukocyte adhesion in rat mesenteric 
microvessels, while FFP conferred protective effects [87]. Resuscitation with fresh whole blood 
can also restore normal endothelial surface levels of the glycocalyx components syndecan-1 and 
heparan sulfate and restore permeability changes in a rat model of HSR when compared to LR 
resuscitation [88]. An additional, innovative study used dried or lyophilized plasma, which can be 
easily maintained, transported and reconstituted, and demonstrated that it has similar properties 
to FFP in protecting endothelial function. It enhanced barrier function and preserved adherens 
junction in vitro, and reduced inflammation and edema in vivo after hemorrhagic shock [89]. These 
studies show that disruption of glycocalyx is involved in HSR-induced permeability, and suggest 
that plasma components can improve barrier dysfunction associated with traumatic conditions. 
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 The endogenous bioactive lipid S1P is one plasma component of particular interest 
because of its endothelial barrier-protective properties and because it is synthesized by 
erythrocytes and platelets [34], which becomes diluted in the blood upon administration of 
crystalloid fluids. As shown by multiple studies, including those outlined in Chapter 2, treatment 
of cultured endothelial cell monolayers with S1P causes an increase in their barrier function, and 
recruitment of junctional proteins such as VE-cadherin and β-catenin to intercellular junctions 
[90,91]. S1P has also been demonstrated to inhibit the degradation, and in fact stimulate, the 
synthesis of components of the glycocalyx such as syndecan-1 and heparan sulfate in endothelial 
cells [92,93]. Moreover, S1P’s contribution to the maintenance of barrier integrity in isolated 
microvessels is associated to preservation of the glycocalyx [94]. In vivo, intravenous 
administration of S1P reduces inflammation and edema formation in the lungs of both rat and 
canine models of LPS-induced microvascular leakage [42,95]. However many questions remain 
about the ability of S1P to restore the structure of the endothelium in vivo during hemorrhagic 
shock or other traumatic injuries, including the mechanism(s) of action. 
 Our laboratory recently demonstrated that administration of S1P during resuscitation 
following combined alcohol intoxication and hemorrhage ameliorated microvascular leakage in 
rat mesenteric microvessels and alleviated hypotension after hemorrhagic shock [44]. However, 
in that particular study we did not investigate the mechanisms of S1P-induced protection of barrier 
function in the context of hemorrhagic shock and resuscitation (HSR). Therefore, in the current 
study we assessed to what extent S1P protects the structure of the microvascular endothelium 
during HSR. We hypothesized that S1P improves microvascular barrier function during HSR by 
preserving intercellular junction structure, preventing loss of the glycocalyx layer and reducing 
inflammation. 
 
3.2 Materials and Methods 
 
 28 
3.2a Pharmacological Agents and Antibodies 
 Sphingosine-1-phosphate (S1P) was obtained from Tocris Biotechne (Minneapolis, MN). 
The polyclonal rabbit anti-VE-cadherin (CD144), and all fluorescence-labeled secondary 
antibodies were obtained from Invitrogen (Carlsbad, CA). Mouse anti--catenin monoclonal 
antibody (L54E2) was purchased from Cell Signaling Technology (Boston, MA). Mouse anti--
actin (C4) horseradish peroxidase-conjugated was from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA). The rabbit anti-Caveolin-1 polyclonal antibody (aa 1-17) was from Abcam (Cambridge, 
MA). Fluorescein isothiocyanate (FITC)-conjugated albumin, FITC-dextran and FITC-lectin were 
purchased from Sigma-Aldrich (St. Louis, MO). Lactated Ringers and 0.9% sodium chloride 
solutions were obtained from Henry Schein (Ocala, FL). All other reagents were obtained from 
Sigma-Aldrich unless otherwise specified. 
 
3.2b Animals 
 This study was approved by the University of South Florida Institutional Animal Care and 
Use Committee (IACUC permit number IS00005044) and performed in accordance with the U.S. 
Animal Welfare Act, U.S. Public Health Service Policy (PHS) on the Humane Care and Use of 
Laboratory Animals and the National Institutes of Health (NIH) Guide for Care and Use of 
Laboratory Animals. 12-15 week old male Sprague-Dawley rats (330 – 355 g) were purchased 
from Envigo (Indianapolis, IL) and housed in a controlled environment (22oC, 12h light/12h dark 
cycle) in the vivarium, and provided a standard diet (Purina Rat Chow, Ralston Purina) and water 
ad libitum for a one-week acclimation period prior to surgery. After the acclimation, surgery to 
implant vascular catheters was performed on anesthetized rats, followed by a one-week recovery 
period, and then the experimental protocols, all detailed below. All animals were humanely 
euthanized with Somnasol Euthanasia-III Solution (87 mg/kg i.v., Henry Schein, Dublin, OH) 
following experimental protocols. 
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3.2c Surgical Preparation 
 The surgical procedures for this model have been recently described in detail by our lab 
and others [44,96,97]. Briefly, the rats were anesthetized with isoflurane, an incision on the ventral 
side of the neck was made, and sterile catheters flushed with 0.9% sterile sodium chloride USP 
(Baxter, Deerfield, IL) were implanted in the left common carotid artery and the right external 
jugular vein. Catheters were secured with a purse-string suture, thermally sealed, subcutaneously 
routed to the dorsal nape of the neck and exteriorized through an incision. The catheters were 
secured to the closed incision with suture, coiled and wrapped with masking tape to prevent the 
rat from accessing it. Carprofen (5 mg/kg subcutaneously; Putney, Portland, ME) was 
administered every 12 h for the first 48 h following surgery to alleviate any pain during recovery. 
Before experiments, animals were allowed to recover for 5 to 7 days in the same conditions as 
the acclimation period. 
 
3.2d Fixed-pressure Hemorrhagic Shock and Resuscitation Protocol 
 After the post-surgery recovery period, rats were subjected to a fixed-pressure 
hemorrhagic shock and resuscitation (HSR) protocol while conscious and unrestrained, as 
previously described [44,97]. A fixed-pressure hemorrhage model was chosen over a fixed-
volume model because constant-pressure models are more reliable for experimental 
standardization and reproducibility [98]. With this method, reliable evaluations of the physiological 
changes in the tissue of interest that occur during a specific central pressure can be made. 
Moreover, the model with conscious, unrestrained rats is superior to other models because 
handling, restraint and anesthetics all significantly impact blood pressure [99,100]. The 
experimental groups were Sham control rats, HSR, and HSR + S1P. The Sham control group 
received the same catheter implantation surgical procedure as the other groups but did not 
undergo the HSR protocol. Briefly, the rats were placed in small cages and the catheters were 
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routed through the top of each cage. The carotid catheter was connected to a pressure transducer 
(ADInstruments PowerLab 4/35 with Quad Bridge amplifier system and LabChart software, 
ADInstruments, Colorado Springs, CO) for continuous blood pressure recording and monitoring 
throughout the whole protocol. The rats were allowed to acclimate by roaming freely in the cage 
for 60 minutes before the start of hemorrhage. At the beginning of hemorrhage, arterial blood was 
withdrawn from the carotid catheter (blood pressure recording is momentarily interrupted at this 
point) to achieve a blood pressure of 50-60 mmHg, which is maintained for 60 minutes. If 
necessary, additional blood was withdrawn during this period to maintain the blood pressure. At 
the end of the 1-h hemorrhage period, warm resuscitation solution (Lactated Ringer’s) was 
delivered intravenously through the jugular catheter as an initial bolus with a volume of 40% of 
the total blood volume removed (TBR) followed by an infusion of 2 X TBR over 60 minutes. For 
the HSR + S1P group, S1P was dissolved in the resuscitation fluid to achieve a dose of 0.1 mg/kg 
for the overall 1-h resuscitation period. Our previous findings from a dose-response study 
demonstrated that this dose is most effective to protect against microvascular permeability 
induced by combined acute alcohol intoxication and HSR [44]. The HSR group received warm 
lactated ringers without S1P for resuscitation.  
 
3.2e in vivo Assessment of Microvascular Permeability 
 Following the HSR protocol, microvascular leakage of the mesenteric microcirculation was 
assessed by intravital microscopy (IVM) as previously described [44,57,97] Briefly, rats were 
anesthetized with isoflurane (4% induction, 2% maintenance), the ventral abdominal fur was 
shaved and the skin was sterilized with 4% chlorohexidine gluconate solution (CareFusion, 
Leawood, KS), 100% ethyl alcohol, and 7.5% Povidone-iodine (Purdue Products L.P., Stamford, 
CT). Next, a midline laparotomy was performed, and a segment of the small intestine and 
associated mesentery was exteriorized, spread out over an optical stage and superfused with 
warm Ringer’s solution. The animal’s body temperature was maintained using a heating plate 
 31 
placed under the rat’s body and monitored by a rectal thermometer. For assessing microvascular 
leakage, FITC-conjugated albumin dissolved in Lactated Ringer’s solution was administered 
intravenously through the jugular catheter as a 1 ml bolus (100 mg/kg) followed by continuous 
infusion (0.15 mg/kg/min). Observation of mesenteric microvessels was done with a fluorescent 
microscope (Nikon Eclipse E600) using a 10X objective (Nikon Instruments Inc., Natick, MA) at 
488 nm excitation. Fluorescent images were captured via Photometrics HQ2 digital camera 
(Photometrics, Tucson, AZ), controlled by MicroManager software.  
3.2e.i Data Analysis: Microvascular Permeability 
 After acquiring images with MicroManager, they were opened with Fiji/ImageJ software. 
Analysis of FITC-albumin extravasation was done by measuring the integrated optical intensity 
(IOI) of extravascular areas close to post-capillary venules [6]. Briefly, at least three regions of 
interest (ROI) were drawn in areas just outside the venules, and the intensity of the grey values 
of the ROIs were measured and averaged to obtain IOI. The number of replicates for each group 
was at least 3 rats. Data were analyzed using one-way ANOVA to detect overall differences, and 
post-hoc assessment with Tukey’s test to detect differences between specific pairs of groups. 
Significance accepted when p < 0.05. 
 
3.2f Immunofluorescence Labeling and Confocal Microscopy of Mesenteric Microvessels 
 For some experiments, immunofluorescence confocal microscopy of the junctional protein 
VE-cadherin on small intestine mesenteric windows was performed following the HSR protocol. 
At the end of the resuscitation period, the rats were anesthetized with isoflurane, a small 
laparotomy was performed, and the small intestine and mesentery were harvested and rinsed in 
ice-cold albumin-physiological salt solution (APSS; 120 mM NaCl, 4.7 mM KCl, 2 mM 
CaCl2·2H2O, 1.2 mM MgSO4·7H2O, 1.2 mM NaH2PO4, 2 mM Na pyruvate, 5 mM glucose, 0.02 
mM EDTA, 3 mM MOPS, and 1% BSA). Rats were then immediately euthanized. A section of the 
mesentery was pinned in a dissection dish containing ice-cold APSS and, with the aid of a 
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dissection microscope, mesenteric windows were carefully dissected from the surrounding tissue. 
Each window was fixed with 4% paraformaldehyde for 15 minutes at room temperature, washed 
twice with 100 mM glycine buffer to quench the fixation, and then washed once with Ca2+/Mg2+-
free Dulbecco’s PBS (DPBS). Windows were then permeabilized with 0.1% TritonX-100 in 1X 
PBS for 30 minutes and washed three times with DPBS for 5 minutes to remove the TritonX-100 
detergent. After permeabilization, windows were blocked in 5% donkey serum in DPBS for 45 to 
60 minutes, and then incubated overnight at 4 °C with anti-VE-cadherin (1:400) or anti-β-catenin 
(1:250) primary antibodies diluted in antibody buffer (151 mM NaCl, 17 mM trisodium citrate, 2% 
donkey serum, 1% BSA, 0.05% Triton X-100, and 0.02% NaN3). After overnight incubation with 
primary antibody, the mesenteric windows were rinsed (four times for 10 min) with an antibody 
wash solution (151 mM NaCl, 17 mM trisodium citrate, and 0.05% Triton X-100) and then 
incubated with secondary antibodies (1:500-diluted AlexaFluor-488 donkey anti-rabbit for VE-
cadherin or AlexaFluor-594 donkey anti-mouse for β-catenin) diluted in antibody buffer for 60 min 
at room temperature, followed by four rinses of 10 min in antibody wash solution. After the last 
wash, each window was splayed on a glass slide with a SecureSeal imaging spacer and 20 µl of 
50% glycerol and covered with a glass coverslip. Confocal image stacks (0.5 - 1 µm z sections) 
of the microvessels in each window were taken with an Olympus FV1200 spectral inverted laser 
scanning confocal microscope with 40X objective at the Lisa Muma Weitz Advanced Microscopy 
and Cell Imaging Core at the University of South Florida. The images were analyzed using Imaris 
image analysis software (Bitplane, Concord, MA). The confocal image stacks were processed 
into maximum intensity z-projections for presentation as figures using ImageJ software.  
 For some experiments, immunofluorescence (IF) labeling of VE-cadherin was performed 
immediately after IVM visualization of the mesenteric windows with FITC-albumin, for correlation 
of endothelial barrier failure with VE-cadherin redistribution, as previously described [101] with 
modifications. Briefly, after IVM animals were euthanized and the mesenteric windows were 
isolated and washed once with Ca2+/Mg2+-free Dulbecco’s PBS (DPBS), followed by immediate 
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incubation with fixative. IF labeling of VE-cadherin was performed normally as described above. 
Because the IVM with FITC-albumin was followed by a light wash with DPBS and immediate 
fixation, areas of FITC-albumin leakage could be identified by observation of extravascular FITC-
albumin labeling [101]. Confocal image stacks (1-µm z-sections) were collected at excitation 
wavelengths of 488 nm (for FITC-albumin) and 594 nm (for secondary antibody for VE-cadherin). 
Images for each fluorophore were collected separately, to eliminate bleed-through due to the 
intensity of FITC-albumin labeling. For presentation, the images from separate channels were 
processed with Fiji/ImageJ software into maximum intensity z-projections and merged.  
 
3.2f.i Data Analysis: Mesenteric Immunofluorescence Images 
 The Z-projection 3-D images were saved as Olympus oib format files and opened for 
analysis using Imaris image analysis software (Bitplane, Concord, MA). Thresholds and 
parameters were determined and ROIs were created around the length of the microvessels. The 
sum of the intensities of the grey values was divided by the area of the ROI to obtain the mean 
intensity value of the vessels. The confocal oib files were exported to Fiji/ImageJ, processed into 
maximum intensity Z-projections and saved as TIF format for presentation. At least three areas 
from different venules in each rat were used for analysis. Significance was determined by one-
way ANOVA followed by Tukey’s multiple comparisons test and accepted when p < 0.05. 
 
3.2g in vivo Measurements of Glycocalyx Thickness and Integrity 
 Integrity of the endothelial surface glycocalyx layer (EGL) was assessed in Sham control, 
HSR and HSR + S1P rats by direct visualization using Bandeiraea simplicifolia (BSI)-lectin 
conjugated to FITC (FITC-lectin; Sigma-Aldrich, St. Louis, MO), which has high specificity for 
sugar moieties and can bind to the polysaccharide side chains that compose the EGL [102,103]. 
Following the experimental protocol, rats were prepared for IVM as described above. Once an 
area with good blood flow was detected, we administered FITC-lectin (6.25 mg/kg diluted in 1 ml 
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saline) via the jugular catheter and allowed for systemic distribution before images were taken 
using the 10X objective at 488 nm excitation. At least three post-capillary venules were used for 
quantification of the EGL in each rat. All vessels were comparable in blood flow and diameter. 
 Additionally, we used the dye-exclusion method [104-106] to estimate the thickness of the 
glycocalyx. After preparing each rat for IVM, a bolus of FITC-labeled dextran (150 kDa) at 50 
mg/kg diluted in 1 ml Ringer’s solution was administered via jugular catheter, and fluorescence 
was allowed to reach a steady level. Post-capillary venules with steady blood flow were selected, 
and both brightfield and fluorescent (488 nm) images were captured with a 10X objective. At least 
three different areas were imaged per rat. 
 
3.2g.i Data Analysis: FITC-lectin  
 After acquiring the images with MicroManager, they were saved in TIF format and opened 
with Fiji/ImageJ software for analysis. A region of interest (ROI) was created by manually tracing 
a measurement path along the wall of each vessel. The grey intensity values of each pixel along 
the path were measured and averaged to obtain the mean integrated optical intensity (IOI) for 
that vessel wall. This IOI was averaged with the average IOI obtained from a path traced on the 
contralateral wall in focus [107]. Significance was determined with one-way ANOVA followed by 
Tukey’s multiple comparisons test, and accepted when P < 0.05. 
3.2g.ii Data Analysis: Dye Exclusion 
 Large-size molecules such as 150-kDa dextrans are excluded from the vessel wall by the 
glycocalyx, so the difference in vessel diameter at a given location between brightfield and 
fluorescence images represents the thickness of the glycocalyx on the two vessel walls [105,106]. 
Briefly, after acquiring brightfield and fluorescent images with MicroManager, they were saved as 
TIF and later opened with ImageJ for analysis. On the brightfield image, a straight line was traced 
from one vessel inner wall to the opposite inner wall and the length of the line was measured in 
microns. This process was repeated on the fluorescent image, measuring the diameter of the 
 35 
luminal FITC-Dextran-150 at the same location as the corresponding brightfield image. The 
difference in vascular widths between the brightfield and fluorescent images was div ided by two 
to obtain the thickness of the glycocalyx for that particular area. This process was repeated at 
least three times along the length of each vessel and the values were averaged to obtain the 
mean glycocalyx thickness. Significance was determined with one-way ANOVA followed by 
Tukey’s multiple comparisons test, and accepted when P < 0.05.  
 
3.2h Leukocyte-Endothelium Rolling and Adhesion 
 Leukocyte rolling and adhesion were analyzed in Sham, HSR and HSR + S1P rats 
following the experimental protocol. Rats were prepared for IVM and mesenteric venules (30 - 60 
µm diameter) with comparable blood flow were selected for visualization of leukocyte dynamics. 
The exteriorized mesenteric was continuously superfused with 37 °C Ringer’s solution. The 
microcirculation was observed using a Nikon Eclipse E600 microscope and 10X objective, and 
rapid time-lapse brightfield image sets were acquired over a 30-s period. The microscope was 
focused above and below the diametral plane in order to capture all leukocytes present in that 
segment.  
 
3.2h.i Data Analysis: Leukocyte Rolling and Adhesion 
 Rolling and adhesion were measured by assessing the frame-by-frame playback of the 
digital image set for individual leukocytes. The number of leukocytes that were rolling in a velocity 
noticeably slower than that of cells in the central blood stream was counted for each selected 
vessel segment, and the length of that segment was also recorded. A leukocyte was defined 
adherent if it remained stationary for at least 5 s. Significance was determined by one-way 
ANOVA, with Tukey’s multiple comparisons test, and accepted when p < 0.05. Leukocyte rolling 
and adhesion are expressed as the number of leukocytes per 100 µm of vessel length as 
previously described [58,108,109].  
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3.2i Western Blotting of Mesenteric Microvessels 
 Following the experimental protocol for each group, some rats were used for protein 
expression analysis of the mesenteric microvasculature. Briefly, at the end of the experiment, the 
rats were humanely euthanized and the small intestine and mesentery were excised and 
immediately placed in a beaker containing ice-cold APSS. The tissue was splayed on a dissecting 
dish and the mesenteric microvasculature was carefully dissected away from the surrounding 
tissue, as previously described [80]. For total protein extraction, the isolated microvasculature 
was homogenized in radioimmunoprecipitation assay (RIPA) lysis buffer containing protease 
inhibitors (Thermo Fisher, Rockford, IL). Tissue homogenates were centrifuged for 15 min at 
14,000 rpm at 4 °C, and the supernatant was collected for protein concentration estimation using 
Pierce’s bicinchoninic acid assay (BCA) kit (Thermo Fisher). Each sample consisted of 
microvessels pooled from 7 - 10 rats per experimental group. To extract the cytosolic protein 
fraction, the microvessels were dissected as described above, and a plasma membrane protein 
extraction kit (Abcam, Cambridge, MA) was used according to the manufacturer’s protocol to 
extract the membrane and cytosolic protein fractions. Our samples yielded concentrations 
sufficient for immunodetection of proteins in the total and cytosolic fractions, but not in the 
membrane fraction by Western blot. The protein samples were heated at 100 °C for 5 minutes 
and subjected to SDS-PAGE, then transferred to polyvinylidene (PVDF) membranes. The 
membranes were blocked for 1 hour at room temperature with 5% bovine serum albumin (BSA) 
in Tris-buffered saline solution with 0.1% Tween-20 (TBS-T) and were incubated with mouse anti-
β-catenin (1:300), rabbit anti-Caveolin-1 (1.5 μg/ml) or HRP-conjugated anti-β-actin (1:1000) 
diluted in blocking solution overnight at 4 °C. The membranes were washed three times with TBS-
T. For the membranes incubated with the anti-β-catenin and anti-caveolin-1 antibodies, an 
additional incubation with HRP-conjugated-anti-mouse IgG secondary antibodies (1:1000) was 
performed at room temperature for 1 h. Following three washes with TBST-T, the protein bands 
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were visualized using the SuperSignal West Pico Chemiluminescent Substrate kit (Thermo 
Fisher, Rockford, IL) and the Chemidoc XRS+ Molecular Imager with Image Lab software (Bio-
Rad, Hercules, CA).  
 
3.2i.i Data Analysis: Western Blot 
 Band intensities were quantified using ImageJ software. Regions of interest were drawn 
around each β-catenin and β-actin bands and the mean grey intensity value was measured. 
Cytosolic -catenin bands were normalized to their respective cytosolic actin levels for 
comparison between groups. Significance was determined using one-way ANOVA for 
comparison between groups, and an unpaired t-test was used to compare the HSR and HSR+S1P 
groups. Significance was accepted at P < 0.05. 
 
3.3 Results  
3.3a S1P Rescued Mean Arterial Blood Pressure and FITC-Albumin Extravasation after 
HSR. 
 To evaluate how S1P impacts HSR-induced hypotension and microvascular leakage 
following HSR, we monitored the mean arterial blood pressure (MAP) throughout the protocol and 
assessed FITC-albumin extravasation by IVM. Administration of S1P in the resuscitation fluid 
(lactated Ringer’s solution) significantly raised MAP at the end of the resuscitation period, 
compared to rats that received lactated Ringer’s only (Fig. 6). When examining microvascular 
leakage, in time-matched Sham rats, the FITC-albumin remained in the luminal compartment of 
the microvessels, with minimal fluorescence intensity in the extravascular space. HSR rats 
showed high levels of fluorescence in the areas surrounding the mesenteric microvasculature. 
Rats that received S1P in their resuscitation fluid had relatively low fluorescence outside the 
vasculature (Fig. 7A). Quantification of these data showed that the HSR group had a significantly 
higher mean integrated optical intensity (IOI) in the extravascular areas near the microvessels 
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compared to sham controls, indicating elevated microvascular leakage of FITC-albumin. HSR rats 
that received S1P (HSR + S1P) had significantly lower IOI compared to HSR rats (Fig. 7B). These 
data suggest that the S1P improves mean arterial pressure after hemorrhage, and attenuates the 
microvascular hyperpermeability induced by HSR, thus preventing loss of central fluid volume.  
 
3.3b Resuscitation with S1P following Hemorrhage Preserved Paracellular Junction 
Protein Integrity. 
 Because the expression and localization of junctional proteins such as VE-cadherin at the 
paracellular junctions is pivotal for endothelial barrier integrity, we performed 
immunofluorescence confocal microscopy of mesenteric post-capillary venules to determine to 
what extent S1P may reduce HSR-induced microvascular leakage by improving junctional 
location of VE-cadherin. Fig. 8A shows that VE-cadherin is localized between endothelial cells in 
Sham rats, outlining a clear boundary for each cell. HSR disrupted the localization of VE-cadherin, 
and also significantly decreased the intensity of labeling. HSR + S1P rats showed high localization 
of VE-cadherin at the junctions, and significantly higher VE-cadherin expression compared to 
HSR rats (Fig. 8A, B). Disorganization of the adherens junctional protein -catenin was also 
observed with HSR, and its localization in the paracellular junction was significantly increased in 
HSR + S1P rats compared to HSR rats (Fig. 8C, D).  
 -Catenin is known to stabilize VE-cadherin and aid in paracellular junction maturation 
and function. Loss of cadherin-mediated adhesion in the cell-cell junction can promote the release 
of -catenin into the cytoplasm, where it acts as a signaling molecule [110]. Moreover, the high 
expression of cadherin molecules at the cell membrane can act as a “trap” for free, cytoplasmic 
-catenin [111]. While immunofluorescence microscopy enabled us to view disorganization of -
catenin in microvessels, it did not allow us to determine the precise membrane or cytosolic 
localization of β-catenin. Therefore, in order to better understand the dynamic changes in -
 39 
catenin localization during HSR, we performed western blot on the mesenteric microvessels 
following experiments. Our results, in which loading of samples was performed after overall 
protein levels in the lysates were equalized, showed no change in the total amount of -catenin 
protein in mesenteric microvessels of sham, HSR or HSR + S1P rats. However, we observed a 
noticeable increase in the cytosolic levels of -catenin following HSR compared to Sham rats. 
HSR + S1P rats had significantly lower cytosolic levels of -catenin compared to HSR rats (Fig. 
9 A, B). To verify cytosolic protein fraction isolation, we also performed Western blots for caveolin-
1, a protein known to be localized to lipid rafts of the plasma membrane, where it performs several 
roles in membrane dynamics [112]. The band intensities for caveolin-1 were lower in the cytosolic 
fraction than those for the total protein fraction of all three groups, indicating successful 
fractionation. Interestingly, higher cytosolic levels of caveolin-1 in the HSR group were observed 
and might indicate its dissociation from membrane caveolae as a response to injury. Given that 
total -catenin expression did not change, this data suggests that HSR causes a shift in -catenin 
localization from the junctions to the cytosol, destabilizing VE-cadherin and contributing for the 
increase in permeability. Treatment with S1P seems to recruit the available -catenin in the 
cytosol back to the paracellular junctions during HSR, and this might be contributing to rescue 
albumin permeability.  
 
3.3c VE-Cadherin Breakdown Correlated with Endothelial Barrier Failure. 
 In order to determine whether adherens junction breakdown correlated with areas of 
microvascular barrier dysfunction, we performed confocal microscopy to examine VE-cadherin 
morphology specifically at areas where endothelial barrier had failed as evidenced by FITC-
albumin accumulation in vessel walls and extravasation. We performed these experiments in rats 
that underwent Sham HSR, HSR or HSR with S1P treatment. Examination of the mesenteric 
venules of Sham and S1P-treated rats showed interendothelial VE-cadherin labeling pattern more 
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often than HSR rats, whereas microvessels of HSR-treated rats consistently revealed a strong 
degree of disruption in the intercellular borders, as evidenced by a diffuse VE-cadherin labeling 
(Fig. 10). Moreover, we observed that VE-cadherin discontinuity corresponded to albumin labeling 
in and just outside the vessel walls, independently of the treatment given (Fig. 10). 
 
3.3d Resuscitation with S1P Protected the Endothelial Glycocalyx Layer (EGL). 
 Hemorrhagic shock and resuscitation has been shown to cause degradation of the EGL 
[85,113]. In the current study, we performed direct visualization of the EGL using fluorescence-
labeled lectin, and we found that HSR caused a significant drop in the accumulation of FITC-lectin 
bound to the walls of post-capillary venules compared to Sham rats (Fig. 11 A, B). Rats that 
received S1P in the resuscitation fluid (HSR + S1P) had significantly higher FITC-lectin 
fluorescence compared to HSR rats (Fig. 11 A, B). We also measured the thickness of the 
glycocalyx in the mesenteric post-capillary venules by using the dye-exclusion method. We found 
that rats subjected to hemorrhage and resuscitation without S1P had significant reduction in 
glycocalyx thickness compared to Sham rats. Rats that received S1P resuscitation displayed 
significantly thicker glycocalyx compared to HSR rats (Fig. 11 C, D). These data suggest that 
S1P’s barrier-protective effects during HSR are partly due to its ability to maintain glycocalyx 
integrity.  
 
3.3e Leukocyte-endothelium Interaction Was Reduced With S1P Administration. 
 Degradation of the glycocalyx plays a role in inducing a pro-inflammatory response and 
promoting leukocyte adhesion to endothelial cells [114,115]. Therefore, as an indicator of the level 
of inflammation, and indirect indicator of glycocalyx integrity, we evaluated leukocyte interaction 
with the endothelium of mesenteric post-capillary venules in Sham, HSR, and HSR + S1P rats. 
All venules chosen were comparable to flow rate and diameter. Leukocyte rolling and adhesion 
data are shown in Fig. 12. Treatment with S1P resulted in significantly lower number of slow-
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rolling leukocytes in mesenteric venules after HSR compared to HSR rats that did not receive 
S1P (Fig. 12A). HSR rats exhibited significantly greater leukocyte adhesion (leukocytes that were 
stationary for 5 seconds or more) to the endothelium compared to Sham rats. This effect was 
reversed by resuscitation with S1P (Fig. 12B). These data support the role of S1P in protecting 
against glycocalyx degradation during HSR, attenuating the inflammatory response that leads to 
disruption of endothelial barrier and hyperpermeability. 
 
3.4 Discussion  
 The complications that arise from fluid resuscitation following hemorrhagic shock remain 
a serious problem, including resuscitation-related changes in endothelial cell function and loss of 
endothelial integrity, contributing to microvascular leakage and edema formation [44]. In this part 
of the study, we demonstrate that S1P protects against microvascular leakage and improves 
blood pressure when administered during resuscitation following hemorrhagic shock. We also 
show that resuscitation with S1P prevents HSR-induced disruption of endothelial junctions and 
the glycocalyx layer. Likewise, rolling and adhesion of leukocytes, which can be facilitated by 
glycocalyx shedding, are also attenuated with S1P treatment. 
 Our findings that S1P can ameliorate HSR-induced hypotension and microvascular 
leakage are in agreement with previous work utilizing administration of S1P or its analog FTY720 
in resuscitation fluids [44,116]. S1P or its mimetics have been shown to reduce microvascular 
leakage in a variety of other animal models, including platelet activating factor- and bradykinin-
induced elevations of hydraulic conductivity in rat mesenteric microvessels [117], histamine-
induced extravasation in the rat cremaster muscle [118], endotoxin-induced acute lung alveolar 
permeability [41], and bleomycin-induced lung edema [119]. The mechanisms involved in S1P-
mediated reduction of microvascular leakage are not completely understood, but involve 
activation of one or more S1P receptors, followed by rapid activation of Rho family small 
GTPases, changes in the cytoskeleton including increased protrusion of local lamellipodia, plus 
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changes in junctional and focal adhesions [64,68,120,121]. In addition, S1P also has been shown 
to promote glycocalyx integrity in cultured endothelial cells [93,94]. As nearly all of the mechanistic 
studies have been performed in cultured cells, our current findings provide novel in vivo evidence 
that S1P is effective at preventing HSR-induced disruption of VE-cadherin and β-catenin 
localization at endothelial junction in combination with preserving glycocalyx integrity. Moreover, 
we provide the first evidence of that microvascular hyperpermeability induced by HSR correlates 
with areas where the organization of the adherens junction VE-cadherin is disrupted. 
 As described above, structural changes that are likely involved in the mechanism of S1P-
mediated barrier enhancement have been elucidated. However, at this stage their linkage in a 
cause-effect paradigm remained to be determined. In the next section of this dissertation, we 
investigate a novel mechanism linking S1P-induced enhancement of paracellular junction protein 
localization, endothelial glycocalyx integrity, and endothelial barrier function during HSR through 
protection of mitochondrial function.  
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Figure 6. S1P Treatment Rescues Hypotension Induced by Hemorrhagic Shock and 
resuscitation (HSR).  
Time-course tracing of mean arterial blood pressure (MAP) of HSR (n = 3) and HSR + S1P (n = 
4) rats during the fixed-pressure HSR. A 30-minute baseline measurement (BL) was taken before 
the start of hemorrhage. Values are shown as means ± SEM, **P < 0.01 between groups at the 
last three time-points of resuscitation. The groups were compared with repeated measures 
ANOVA and Fisher’s LSD test. 
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Figure 7. S1P Treatment Rescues hemorrhagic-shock and Resuscitation-induced 
Microvascular Leakage. 
 
A. Representative fluorescent images of the mesenteric microvasculature of Sham (N = 3), HSR 
(N = 4), and HSR + S1P (N = 3) groups. Arrows indicate “hot-spots” of albumin leakage just 
outside the vessel wall. The circles show areas of albumin leakage into the extravascular space. 
B. Quantification of FITC-albumin extravasation was done by measuring the integrated optical 
intensity (IOI) in the extraluminal space adjacent to postcapillary venules. **P < 0.01, *P < 0.05 
(one-way ANOVA, with Tukey’s multiple comparisons test). 
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Figure 8. Resuscitation with S1P preserves adherens junction organization and expression 
following hemorrhage.  
A, C. Representative maximum intensity confocal z-projections of immunofluorescence-labeled 
VE-cadherin (green) and β-catenin (red) in mesenteric windows from Sham (N = 4), HSR (N = 5), 
and HSR + S1P (N = 4) rats. The representative images show disorganization of the junctional 
protein pattern in post-capillary venules following HSR, in contrast to organized localization 
between endothelial cells in the sham group and HSR + S1P group. B, D. Quantification of VE-
cadherin and β-catenin expression on the microvessels was done using the Imaris image analysis 
software, and is shown as integrated optical intensity (IOI) of the vessel area. At least three 
windows from each rat were used for quantification. *P < 0.05 (one-way ANOVA followed by 
Tukey’s test). 
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Figure 9. HSR Increases Cytosolic Expression of β-catenin, and Resuscitation with S1P 
Reverses this Effect. 
A. Representative Western Blot showing an increase in the cytosolic concentration of β-catenin 
following HSR. Specific antibodies were used to determine β-catenin expression in dissected 
mesenteric microvessels. In the HSR + S1P group, an apparent decrease in cytosolic expression 
of β-catenin, with no apparent change in total protein expression was observed. Caveolin-1, a 
protein that is expressed on the plasma membrane of most cell types, is shown as a control for 
cytosolic fraction separation. These data suggest a shift in β-catenin and caveolin-1 localization 
during HSR. Pooled samples of microvessels isolated from 7 - 10 rats were needed for sufficient 
protein for analysis. B. Quantification of the β-catenin band intensity from multiple Western blots. 
The data represent N = 2 pooled samples for sham, N = 3 pooled samples for HSR, and N = 4 
pooled samples for HSR + S1P. *P < 0.05, HSR vs. HSR + S1P (unpaired t-test). The sham group 
was not used in the statistical analysis and is only shown for visual comparison. 
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Figure 10. Correlation of VE-cadherin disruption with endothelial barrier dysfunction. 
Representative confocal images showing colocalization of VE-cadherin immunofluorescence 
labeling and sites of FITC-albumin permeability in mesenteric microvessels of Sham, HSR, and 
HSR + S1P rats. Disruption in VE-cadherin organization following HSR colocalizes with FITC-
albumin labeling around the microvessel. 
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Figure 11. S1P protects the mesenteric microcirculation against glycocalyx degradation 
induced by HSR.  
A. Representative images showing FITC-lectin binding to the endothelial glycocalyx on the vessel 
walls of post-capillary venules. FITC-lectin was administered intravenously following the sham, 
HSR, or HSR + S1P protocols. Sham rats present high concentration of lectin bound to the venular 
wall, while HSR rats have much smaller amounts of FITC-lectin fluorescence, as indicated by the 
arrows. Animals that received resuscitation with S1P (HSR + S1P) retain FITC-lectin on the 
endothelium. B. Analytical quantification of FITC-lectin bound to the walls of post-capillary 
venules. Each data point represents the average integrated optical intensity (IOI) of at least 3 
separate vessels in one rat. **P < 0.01, *P < 0.05 for the indicated groups, one-way ANOVA 
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followed by Tukey’s multiple comparisons test. N=3 rats in each group. C. Measurement of rat 
mesenteric microvascular glycocalyx thickness using FITC-dextran (150 kDa) exclusion assay 
was performed with brightfield and fluorescent images of mesenteric venules. D. Quantification 
of glycocalyx thickness from the imaging data is shown. Each data point represents the average 
of glycocalyx measurements on 4 - 8 vessel areas per rat. **P < 0.01, one-way ANOVA, with 
Tukey’s multiple comparisons test. N = 3 rats per group. 
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Figure 12. Resuscitation with S1P decreases leukocyte-endothelium interactions following 
hemorrhage. 
A. S1P administration during resuscitation after hemorrhage significantly reduces the number of 
slow-rolling leukocytes in mesenteric postcapillary venules, compared to HSR alone. B. The 
number of leukocytes firmly adhered to the endothelium following HSR is significantly higher than 
sham control rats. Resuscitation with S1P significantly decreases firm leukocyte adhesion. *P < 
0.05 (one-way ANOVA, with Tukey’s multiple comparisons test) for the indicated groups. Sham 
group, N = 3; HSR, N = 6; HSR + S1P, N = 4. 
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Chapter Four: 
S1P Protects Endothelial Glycocalyx/Junctional Structure and Barrier Function by 
Limiting Mitochondrial Depolarization 
4.1 Introduction 
 The mitochondria are the key metabolic regulators in most types of cells. In 
addition to their classic role in the aerobic production of ATP, they regulate a variety of processes 
from cell proliferation, to apoptosis and nuclear signaling [122-124]. However, the mitochondrial 
content of endothelial cells is relatively modest. In rat endothelial cells, they occupy only 2 - 6 % 
of the cell volume, in contrast to 28 % in hepatocytes and 32 % in cardiac myocytes [125]. Indeed, 
endothelial cells obtain a great portion of their energy from anaerobic glycolysis [126], from where 
they generate more than 80% of their ATP [127]. Although the mitochondria are not the main 
source of energy production in endothelial cells, they do have important signaling roles in the 
vascular endothelium [125]. For example, the mitochondria are considered important regulators 
of the intracellular calcium buffering system in endothelial cells. Although the ER is the major site 
for calcium storage, up to 25 % of cellular calcium is located in the mitochondria [125]. The 
mitochondria and the ER have been shown to operate together to regulate calcium trafficking in 
endothelial cells [128]. Calcium signaling regulates the actin cytoskeleton in endothelial cells, 
influencing cell motility, shape, and barrier function [129]. Mitochondrial reactive oxygen species 
(mROS) are also associated to endothelial cell dysfunction, apoptosis, and senescence. Altered 
mitochondrial dynamics has been associated with endothelial dysfunction in patients with vascular 
diseases such as diabetes mellitus, atherosclerosis and hypertension [130,131]. Although 
mitochondrial dysfunction has been associated to endothelial cells in diseases that involve 
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vascular damage, the direct mechanisms of mitochondria-induced disruption of endothelial barrier 
are still unknown.  
 Previous studies have demonstrated that activation of the mitochondrial intrinsic apoptotic 
signaling pathway could play a role in HSR-induced hyperpermeability in vivo. They reported that 
hemorrhagic shock resulted in an increase in the expression of the pro-apoptotic protein BAK, 
disruption in mitochondria transmembrane potential with release of cytochrome-c into the 
cytoplasm, and caspase-3 activation. In vivo transfection of BAK had similar effects [80]. 
Caspase-3 is responsible for proteolytic cleavage of β-catenin, which maintains endothelial cell 
morphological homeostasis by associating with VE-cadherin and protecting it from degradation 
[132,133]. Besides that, the mitochondrial complex III was shown to be involved in endothelial 
hyperpermeability induced by BAK protein in vitro [134]. Interventions to rescue or improve 
mitochondrial functions during the pathogenesis of various vascular diseases have been 
proposed as potential strategies to improve vascular conditions in both animal models and human 
patients [125]. 
 S1P is an important regulator of cell viability and survival by modulating apoptotic 
signaling. Activation of S1PR1 has been shown to decrease cell death by preventing 
mitochondrial dysfunction [135,136]. The role of S1P in supporting mitochondrial function 
specifically has been elegantly showed in a recent study. They investigated how T-cells survive 
for years while constantly traveling, and their results suggest that S1PR1 signaling is required for 
T-cells to maintain mitochondrial content and function, providing them with energy to continue 
their constant migration [135]. In a study about the neuroprotective effects of S1P in an in vitro 
model of ischemia, they found that treatment with S1P reduced oxygen-glucose depravation 
(OGD)-induced mitochondrial inner membrane depolarization and also reduced the increase in 
mitochondrial Ca2+ during OGD [136], suggesting a mechanism of S1P-mediated enhancement 
of cell viability. 
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 In this part of the dissertation, we investigated the role of the mitochondria in mediating 
endothelial barrier integrity and function, and tested a possible mechanism of S1P-mediated 
endothelial barrier protection through the mitochondria. We hypothesized that disruption of 
mitochondrial membrane potential induces endothelial barrier dysfunction through breakage of 
junction proteins and glycocalyx, and S1P is able to reverse these effects by protecting 
mitochondrial function. 
 
4.2 Materials and Methods 
 
4.2a Pharmacological Agents and Antibodies 
 JC-1, a fluorescent mitochondrial membrane potential sensor, was obtained from 
Invitrogen (Carlsbad, CA). The mitochondrial complex III inhibitor Antimycin-A and the ionophore 
Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP), both inducers of mitochondrial 
depolarization by disrupting different aspects of the electron transport chain, were purchased from 
Abcam (Cambridge, MA). The mouse monoclonal cytochrome-c antibody (37BA11) was also 
purchased from Abcam. Mouse monoclonal anti-heparan sulfate antibody (F58-10E4) was 
obtained from Amsbio (Cambridge, MA). Polyclonal rabbit anti-ZO-1 (Mid) was purchased from 
Invitrogen (Carlsbad, CA). Mouse monoclonal anti-β-catenin (L54E2) was obtained from Cell 
Signaling Technologies (Boston, MA). The rabbit anti-BAK (N-terminus) and anti-fractin (C-
terminus) polyclonal antibodies were obtained from Millipore (Burlington, MA). All fluorescence-
labeled secondary antibodies were obtained from Invitrogen. 
 
4.2b Cell Culture 
 Rat Primary Intestinal Mesenteric Vascular Endothelial Cells (RIMEC) and complete rat 
endothelial cell medium (ECM) were purchased from Cell Biologics (Chicago, IL). The cells were 
grown in ECM on 0.2 % porcine gelatin matrix (Sigma-Aldrich, St. Louis, MO) in a 37°C and 5 % 
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CO2 incubator. The ECM was designed and optimized for the culture of rat endothelial cells. It 
contains 2% fetal bovine serum (FBS), epidermal growth factor (EGF), vascular endothelial 
growth factor (VEGF), L-glutamine, and antibiotic-antimycotic solution. On the day of experiments, 
the ECM was replaced with basal ECM (bECM), a serum-free basal medium that lacks FBS and 
the other growth factors found in ECM to minimize confounding effects of these additives on 
experimental outcomes. 
 
4.2c Animals 
 The in vivo experiments described in this chapter were done with Sprague Dawley rats, 
using the same surgical preparation and HSR protocol described in Chapter 3, sections 3.2b-e. 
All experiments were performed after IACUC approval and in accordance with PHS guidelines 
and the NIH Guide for Care and Use of Laboratory Animals. 
 
4.2d in vivo Assessment of Mitochondrial Transmembrane Potential 
 Following the HSR protocol, some rats were prepared for in vivo visualization of 
mitochondrial transmembrane potential of mesenteric microvessels using IVM. Once animals had 
a section of their small intestine and mesentery exposed on an optical stage, the mesentery was 
superfused with warm JC-1 solution (10 µg/ml in sterile 0.9% saline). Before image capture, the 
JC-1 was rinsed off the mesentery. JC-1 exhibits potential-dependent accumulation within the 
mitochondria and its response is specific to depolarization [137]. JC-1 is able to enter the matrix 
of healthy mitochondria, where it selectively accumulates and forms aggregates that fluoresce in 
red. When the mitochondrial membrane depolarizes, JC-1 cannot accumulate, remaining in the 
cytoplasm as a monomeric green fluorescent form [80]. Consequently, a decrease in the 
red/green fluorescence intensity ratio indicates mitochondrial depolarization. Images were 
captured with a 20X objective, by exciting both the monomer and the J-aggregate at 488 nm, and 
detecting green and red emission at 530 and 590 nm wavelengths.  
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4.2d.i Data Analysis: in vivo Mitochondrial Membrane Potential 
 The TIF image files obtained during IVM were opened with ImageJ for analysis of 
mitochondrial function. The multi-channel images were split into single emission channels and the 
brightness and contrast were adjusted for viewing but without altering the original pixel data. Using 
the green channel image, which was easier to visualize the vessel, a ROI was created along the 
length of a vessel wall, and the grey intensity value of each pixel along the ROI was measured 
and averaged to obtain the mean IOI. The same ROI was used in the red channel image to obtain 
the mean IOI. The same process was repeated on the contralateral wall of the same vessel. 
Changes in mitochondrial membrane potential were determined by calculating the red to green 
fluorescence intensity ratio on each vessel wall and averaging the values of at least three areas 
for each rat. Significance of differences between means was determined by one-way ANOVA 
followed by Tukey’s multiple comparisons test, and accepted when P < 0.05.  
 
4.2e Assessment of Apoptotic Signaling Activation in Mesenteric Microvessels 
 In order to determine activation of apoptotic signaling on mesenteric microvessels 
following experimental protocol, we performed immunodetection by western blot (WB) of pro-
apoptotic protein BAK, cytosolic Cytochrome-c, and Fractin, a novel marker for caspase-3 activity 
[138]. The procedure of protein extraction, immunodetection and data analysis by WB in 
mesenteric microvessels has been described in Chapter 3, section 3.2i. The BAK and fractin 
antibodies were used at 1:500 and 1:1000 dilutions, respectively. The mouse monoclonal 
cytochrome-c antibody was used at concentration 1 μg/ml. 
 
4.2f Transendothelial Electrical Resistance 
 RIMEC were grown to confluence in complete endothelial cell medium (ECM) containing 
2% fetal bovine serum (FBS) at 37 °C and 5% CO2. Cells were seeded onto gold electrode arrays 
pre-coated with 0.2% gelatin for assessment of transendothelial electrical resistance (TER) using 
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the ECIS system, as described in Chapter 2, section 2.2b. Vehicle (bECM), Antimycin-A (10 μM) 
or CCCP (10 µM) were added at time = 0, immediately followed (~1 min later) by addition of S1P 
(1 µM) or vehicle, and the TER was recorded for 10 hours to determine changes in barrier function 
over time. 
 
4.2f.i Data Analysis: Transendothelial Electrical Resistance 
 After each experiment, the data text file produced by the ECIS software was opened as 
comma-separated values in Microsoft Excel for analysis. The “0-min” time-point is defined as the 
time when the first treatment was applied to the monolayer. All data points were normalized to 
the 0-min time point, and the TER values for each treatment at each time-point recorded were 
averaged. The data is presented as the mean resistance ± S.E. for each hour following treatment 
vs. time in hours. N = 5 independent experiments were performed, with 4 - 8 monolayers per 
group in each experiment. Statistical analysis of normalized TER was done with repeated-
measures ANOVA followed by Tukey’s multiple comparison test, and significance was accepted 
if p < 0.05. 
 
4.2g in vitro Assessment of Endothelial Cell Death 
 RIMECs were seeded on 6-well plates pre-coated with 0.2% gelatin for analysis of 
cytosolic levels of cytochrome-c by immunodetection. Cells were allowed to grow to confluence 
in complete ECM, at 37 °C and 5% CO2. Before the experiment the medium was changed to 
bECM (vehicle) and cells were allowed to equilibrate for 1 h. Vehicle (bECM), Antimycin-A (10 
μM) or CCCP (10 µM) were added, immediately followed (~1 min later) by addition of S1P (1 µM) 
or vehicle. The conditions of treatment were 37 °C and 5% CO2, and the total time was 5 h. 
Cytosolic protein extraction was done using the Plasma Membrane Protein Extraction Kit (Abcam, 
Cambridge, MA) according to the manufacturer’s protocol. Samples were subjected to protein 
concentration estimation using Pierce’s bicinchoninic acid assay (BCA) assay kit (Thermo Fisher), 
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followed by immunodetection and analysis using the WES Separation Module system (Protein 
Simple, San Jose, CA) according to the manufacturer’s instructions. 
 
Propidium Iodide Viability Assay 
 In order to assess cell viability following AA or CCCP treatment, we used propidium iodide 
(PI) staining, according to the manufacturer’s protocol (Life Technologies, Carlsbad, CA). Briefly, 
RIMECs were seeded onto gelatin-coated 35-mm glass bottom dishes (MatTek Corporation, 
Ashland, MA) and allowed to grow to confluence. On the day of the experiment the medium was 
changed for bECM and allowed to equilibrate for 1 hour. Cells were treated with vehicle, AA or 
CCCP and the total time of treatment was 5 hours. After the various treatments, cells were rinsed 
and equilibrated with a PI solution for 15 minutes at 37 °C, according to the manufacturer’s 
instructions. After 15 minutes, cell viability was assessed using an ASI Imaging Rapid Automated 
Modular Microscope system (ASI Imaging, Eugene, OR) with a 40X objective and 
Micromanager/ImageJ software for image collection. Each treatment was repeated 5 times. In 
each petri dish, a field of view was selected at random and the number of PI-positive cells were 
counted and divided by the number of total cells. 
 
4.2h in vitro Immunofluorescence (IF) of Endothelial Glycocalyx and Junction Proteins 
 RIMEC were grown at 37 °C and 5 % CO2, as described above, and seeded onto glass 
coverslips pre-coated with 0.2 % gelatin and allowed to mature for 3 days post confluence. 
Medium was changed every other day. On the day of the experiment, the medium was changed 
to 37 °C bECM 30 minutes before treatment. Cells were treated with either vehicle (bECM) or AA 
(10 µM), followed by treatment with S1P (1 µM) for 1 hour. For labeling of the endothelial 
glycocalyx, cells were washed once with DPBS and fixed with 2% paraformaldehyde (PFA) and 
0.1 % glutaraldehyde solution in DPBS for 30 min. After fixation, PFA was rinsed with DPBS and 
cells were blocked with 2 % donkey serum in DPBS for 1 hour. Cells were incubated with mouse 
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monoclonal anti-heparan-sulfate antibody overnight at 4 °C. Three washes of 10 min each were 
done with DPBS, followed by incubation with secondary donkey anti-mouse antibody conjugated 
to Alexa Fluor 488 for 1 hour at room temperature. After three washes of 10 min with DPBS, the 
coverslips were mounted onto slides with Prolong Gold antifade reagent with DAPI (Invitrogen, 
Carlsbad, CA). For the junction proteins ZO-1 and β-catenin, the same IF labeling protocol was 
followed as described in Chapter 2, section 2.2e. Confocal images were taken with an Olympus 
FV1200 spectral inverted laser scanning confocal microscope with a 60X objective at the Lisa 
Muma Weitz Advanced Microscopy and Cell Imaging Core at the University of South Florida. The 
image stacks were processed and analyzed using ImageJ.  
 
4.2h.i Data Analysis: Glycocalyx Immunofluorescence 
 The confocal images were saved as Olympus oib files and opened later with ImageJ for 
analysis. Regions of interest (ROI) were drawn in the four quadrants of each field of view, and the 
intensities of the grey values of that ROI were measured and averaged to obtain the integrated 
optical intensity (IOI) for that field of view. The IOIs of three areas for each experiment were 
averaged and presented as an estimate of Heparan Sulfate expression (± SEM). Significance of 
differences between means was determined by one-way ANOVA with Tukey’s multiple 
comparisons test, and accepted when P < 0.05. 
 
4.2i in vitro Assessment of Mitochondrial Membrane Potential 
 Rat Primary Intestinal Mesenteric Vascular Endothelial Cells (RIMEC) were grown to 
confluence in complete endothelial cell medium (ECM) containing 2% fetal bovine serum (FBS) 
at 37 °C and 5% CO2. For live-cell imaging of mitochondrial function, the cells were seeded onto 
glass-bottom dishes pre-coated with 0.2 % gelatin and allowed to mature for 3 to 5 days post 
confluence. On the day of the experiment the medium was changed to warm basal endothelial 
cell medium (bECM) containing JC-1 (2 µg/ml) and allowed to stabilize at 37 °C for 15 min. The 
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dye-containing medium was washed off with basal medium and the cells were randomized into 
groups that were treated with bECM (controls), bECM containing antimycin-a (10 µM final 
concentration), or treated with antimycin-a followed by S1P treatment (1 µM final concentration). 
At 10 min post-treatment, images were captured with a Olympus FV1200 spectral inverted laser 
scanning confocal microscope using a 40X objective, by exciting JC-1 monomer at 488 nm and 
selectively exciting the J-aggregate at 554 nm, and detecting green and red emissions at 530 and 
590 nm.  
 
4.2i.i Data Analysis: in vitro Mitochondrial Potential 
 The confocal images were saved as oib Olympus format files and transferred to ImageJ 
for analysis. The multi-channel images were split into single emission channels. In each field of 
view analyzed, a region of interest (ROI) was created around each individual cell on both red and 
green emission channels. The mean grey value intensity of the ROI was measured and expressed 
as integrated optical intensity (IOI). The IOI of the red channel was divided by the IOI of the green 
channel for each cell. The red/green IOI values (mean ± SEM) of at least 4 cells per field-of-view 
is presented as a measurement of mitochondrial depolarization levels. Significance of the 
differences between means was determined by one-way ANOVA followed by Tukey’s multiple 
comparisons test, and was accepted when P < 0.05. 
 
4.3 Results 
 
4.3a Resuscitation With S1P Protects Mitochondrial Function. 
 Previous studies have reported that changes in mitochondrial function in response to HSR 
could be associated with microvascular hyperpermeability [80]. In order to assess the effects of 
S1P in mitochondrial function of mesenteric microvessels in the context of HSR, we used intravital 
observation of microvessels loaded with the mitochondrial membrane potential sensor JC-1. In 
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cells with healthy mitochondria, some JC-1 exists as a monomeric form in the cytosol (green 
fluorescence) and but a significant portion also accumulates in the mitochondria and forms 
aggregates, fluorescing red. Upon depolarization, JC-1 cannot accumulate in the mitochondria 
and produces only green fluorescence [139]. Mitochondrial depolarization is seen as a decrease 
in the red to green fluorescence ratio. We found that HSR caused mitochondrial depolarization in 
mesenteric postcapillary venules, as seen as a significant decrease in red/green ratio when 
compared to sham rats (Fig. 13). Treatment with S1P during resuscitation protected mitochondrial 
membrane potential and reversed the effect of HSR, significantly increasing red/green 
fluorescence ratio (Fig. 13). 
 
4.3b HSR Does Not Induce Apoptotic Signaling Activation on Mesenteric Microvessels. 
 Previous studies have associated “intrinsic” apoptotic signaling activation to microvascular 
permeability using a different model of HSR, in which rats were anesthetized [80]. In order to 
investigate whether the increase in microvascular permeability observed in our studies could be 
due to endothelial cell death, we subjected the mesenteric microvasculature to immunoblot 
analysis of pro-apoptotic proteins BAK, cytochrome-c and fractin. Fractin is the name given to the 
N-terminal fragment of β-actin when cleaved by activated caspases. It has been established as a 
marker for caspase-3 activity, and it is used to distinguish apoptotic from necrotic cells [138]. Our 
results showed no significant difference in the levels of BAK in mesenteric microvasculature 
following HSR. The expression levels of cytosolic cytochrome-c and fractin were also not 
significantly changed (Fig. 14). These data suggest that, even though HSR caused disruption of 
mitochondrial membrane potential, apoptotic signaling and caspase activation were not involved 
in microvascular permeability in our model of HSR. This led us to hypothesize that: 1) apoptotic 
signaling activation is not necessarily involved in endothelial permeability induced by 
mitochondrial dysfunction; and 2) S1P-mediated attenuation of microvascular permeability is 
associated with its ability to promote normal mitochondrial function on endothelial cells. 
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4.3c Mitochondrial Complex III is Involved in S1P-mediated Endothelial Barrier 
Enhancement.  
 To directly test whether mitochondrial depolarization impairs the endothelial barrier, we 
treated cultured rat intestinal mesenteric endothelial cells (RIMEC) with two different inhibitors of 
oxidative phosphorylation: the ionophore Carbonyl Cyanide m-chlorophenyl Hydrazone (CCCP), 
and the inhibitor of mitochondrial respiratory chain complex III antimycin-A (AA) [140], that has 
been previously been associated with endothelial monolayer permeability [134]. Fig. 15A shows 
a time course of changes in TER, an index of endothelial barrier function, for RIMEC treated with 
vehicle alone (control), AA + Vehicle or AA + S1P. AA treatment immediately caused the TER to 
begin to drop and the reduction in TER was sustained throughout the time course. For the cells 
treated with S1P given just after the addition of AA, only a small drop in TER occurred, which was 
insignificant compared to control (Fig. 15A), indicating that S1P is able to protect RIMEC from 
AA-induced barrier dysfunction. Fig. 15B shows the time course changes in TER of RIMEC 
treated with vehicle control alone, CCCP + Vehicle or CCCP + S1P. Treatment with CCCP caused 
the TER to gradually decrease throughout the 11-hour time course. Treatment with S1P following 
the addition of CCCP was not able to significantly rescue the drop in TER (Fig. 15B). These data 
indicate that disruption of mitochondrial membrane leads to endothelial barrier dysfunction, and 
that complex III is involved in the maintenance of barrier function. Moreover, S1P is able to rescue 
barrier dysfunction induced by complex III inhibition. 
 To investigate whether endothelial cell death could be involved in AA- and CCCP-induced 
barrier dysfunction, we analyzed cytosolic levels of cytochrome-c, and measured cell viability 
using PI stain. Treatment with AA or CCCP was not correlated with significant changes in 
cytochrome-c levels in the cytosol (Fig. 16 A, B). PI stain analysis did not show an increase in cell 
death upon AA or CCCP treatment (Fig. 16 C, D). These data support our in vivo data (Fig. 14) 
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and suggest that endothelial barrier dysfunction induced by mitochondrial membrane disruption 
does not necessarily involve cell death. 
 
4.3d S1P Protects Against Paracellular Junctional Disruption and Glycocalyx Degradation 
Induced by Mitochondrial Complex III Inhibition. 
 Mitochondrial complex III has been reported to be involved in endothelial permeability 
induced by BAK transfection. In order to determine whether the complex III is involved in the 
maintenance of paracellular junctional structure, we treated RIMEC with AA and assessed the 
morphological changes in tight and adherens junction proteins ZO-1 and β-catenin. AA caused 
disruption of ZO-1 and β-catenin organization and formation of paracellular gaps. Treatment with 
S1P following addition of AA maintained the localization of β-catenin, and preserved the 
continuous expression of ZO-1 between endothelial cells (Fig. 17). 
 In order to assess whether the complex III inhibition causes degradation of the endothelial 
glycocalyx layer (EGL), we treated cells with AA and evaluated the surface expression of the 
glycocalyx component heparan sulfate (Fig. 18). We found that treatment with AA degraded 
heparan sulfate surface expression on cultured RIMEC. Treatment with S1P after AA preserved 
the surface expression of heparan sulfate (Fig. 18A, B). These results suggest that normal 
mitochondrial complex III activity, and by extension normal mitochondrial membrane integrity, are 
required for normal maintenance of junction proteins and the EGL, and show that S1P has the 
potential to attenuate endothelial structure disorganization caused by mitochondrial dysfunction 
during inhibition of mitochondrial complex III. 
 
 
 
4.3e S1P Inhibits Mitochondrial Depolarization Caused by Blockade of Mitochondrial 
Complex III Activity. 
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 In order to support our in vivo findings that S1P protects mitochondrial function by blocking 
mitochondrial depolarization, we performed imaging of live RIMEC loaded with JC-1 and treated 
with antimycin-a in the absence or presence of S1P (Fig. 19). We found that inhibition of complex 
III with AA caused depolarization of the mitochondria in RIMEC monolayers, and that treatment 
with S1P after AA was able to rescue this effect (Fig. 19). This result shows that S1P-induced 
protection of mitochondrial function is likely due its ability to protect against inhibition of 
mitochondrial respiratory chain complex III. These results also suggest that S1P-induced 
protection of endothelial barrier function is due to its ability to protect against mitochondrial 
depolarization at the level of complex III. 
 
4.4 Discussion  
 In this series of experiments, we tested our hypothesis that disruption of mitochondrial 
function could lead to endothelial barrier dysfunction through disruption of junction protein 
organization and glycocalyx integrity, and that S1P could rescue this effect. Consistent with 
previous reports [80], we show that HSR causes a disruption in mitochondrial transmembrane 
potential and depolarization in mesenteric venules, suggesting the mitochondria as potential 
modulators of endothelial barrier function. In addition, we provide the novel finding that S1P 
administration in the resuscitation fluid attenuates the HSR-induced disruption of mitochondrial 
membrane integrity. Even though we show that mitochondrial depolarization occurs during HSR, 
analysis of proapoptotic proteins BAK, cytosolic cytochrome-c and the caspase-mediated 
fragmentation of β-actin (fractin), in which no differences were observed between the different 
treatment groups, suggest no activation of apoptotic signaling in HSR when performed in 
conscious, unrestrained rats.  
 To determine whether protection of mitochondrial membrane potential may mediate S1P-
induced attenuation of microvascular leakage caused by HSR, we utilized a cultured RIMEC 
model in which we could study the direct impact of mitochondrial disruption on endothelial barrier 
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function. The results demonstrate that mitochondrial depolarization occurs after inhibition of 
mitochondrial complex III with AA [141] or uncoupling of the proton gradient with CCCP, both of 
which also cause endothelial barrier dysfunction. These results support previous reports that 
complex III is indeed involved in endothelial cell hyperpermeability [134]. However, those studies 
showed involvement of complex III in BAK-induced endothelial hyperpermeability, with AA alone 
having no impact in the basal permeability. Our results, which arose utilizing a more sensitive 
assay for barrier function, ECIS, differ from those studies by showing that complex III is in fact 
involved in endothelial barrier function. In addition, our results show that normal activity of 
complex III is required for the maintenance of junctional proteins and the glycocalyx. Taken 
together with previous reports that direct disruption of the glycocalyx increases endothelial 
permeability [92,93], our findings suggest that complex III activity, and by extension normal 
mitochondrial function, helps maintain the microvascular barrier by promoting a healthy glycocalyx 
layer on endothelial cells. Moreover, our in vitro studies show that mitochondrial membrane 
disruption can lead to endothelial permeability without activation of apoptotic signaling, or cell 
death, ruling out these pathways. We also present the novel finding that treatment with S1P 
partially restores the AA-induced loss of mitochondrial membrane potential, in combination with 
prevention of 1) AA-induced shedding of the glycocalyx component heparan sulfate, and 2) AA-
induced barrier dysfunction.  
 Collectively, the current results, in context with the previous literature, suggest that S1P-
induced enhancement of endothelial barrier function is due at least in part to stabilization of 
mitochondrial membrane potential, which in turn promotes junctional and glycocalyx integrity. 
These results also show that S1P can protect the mitochondrial membrane from disruptions of 
the mitochondrial transport chain at the level of Complex III.  
 An interesting part of our results is that S1P only partially rescues mitochondrial 
depolarization induced by AA (Fig. 19 B). However, our data show that S1P completely reverses 
the effect of AA on endothelial barrier function (Fig. 15 A), which is accompanied by significant 
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preservation of junctional proteins and the glycocalyx. This either suggests that S1P’s ability to 
block mitochondrial depolarization is sufficient to maintain barrier function, or that S1P signaling 
compensates for other pathways downstream of complex III. The production of reactive oxygen 
species (ROS) during endothelial injury and disruptions in the calcium signaling mechanism might 
provide a possible explanation for S1P-induced protection during mitochondrial dysfunction. 
During inflammatory state conditions, there is an increase in levels of cytosolic calcium, due to 
release from the ER or extracellular calcium influx. This results in increased mitochondrial calcium 
levels, enhanced activity of the electron transport chain, and subsequent superoxide production 
[142]. The mitochondrial complex III has been regarded as a main source of superoxide [143], 
which upon release into mitochondrial matrix and inter-membrane space, is converted to 
hydrogen peroxide, elevating mROS levels. Mitochondrial ROS can diffuse to the cytoplasm, 
where it interacts with and modifies calcium signaling, usually resulting in further increase in 
intracellular free calcium levels [142]. The stability and control of vascular barrier function is 
dependent on calcium-based homotypic linkage between neighboring adherens junction proteins, 
such as VE-cadherin [95]. S1P is implicated in mediating the interaction between adheres junction 
proteins and the actin cytoskeleton through enhancing the interaction between the actin-binding 
proteins cortactin and endothelial myosin light chain kinase (MLCK), an event that is dependent 
on calcium. Treatment of endothelial cells with S1P rapidly localizes both of these proteins to the 
cell periphery, where they participate in rearranging the cytoskeleton, leading to enhanced barrier 
function [55]. The elevation in intracellular levels of calcium that occurs during mitochondrial 
dysfunction, particularly dysfunction of complex III, might intensify the ability of S1P to mediate 
the interaction between cortactin and MLCK, possibly explaining the overshoot in TER above 
baseline levels observed when AA-treated cells are co-treated with S1P (Fig. 15A). This 
mechanism of S1P-mediated endothelial barrier protection during mitochondrial dysfunction is a 
possibility for future investigation. 
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Figure 13. S1P protects against HSR-induced mitochondrial dysfunction.  
A. Representative in vivo IVM of mesenteric windows from the sham, HSR and HSR + S1P 
groups. In sham rats, JC-1 aggregated in the mitochondria of post-capillary venules and 
fluoresced red (590 nm images), indicating healthy mitochondria. HSR rats show impaired 
mitochondrial membrane integrity, causing elevated diffusion of JC-1 to the cytoplasm (green 
fluorescence, 530 nm images) and decreased red aggregate. S1P-treated rats show intact 
mitochondria as JC-1 red aggregate. B. Analysis of red to green fluorescence ratio in the walls of 
post-capillary venules show that HSR causes significant mitochondrial depolarization, which is 
rescued by resuscitation with S1P. Each dot represents the average ratio value for one rat. *P < 
0.05, ***P < 0.01. The groups were compared with one-way ANOVA and Tukey’s multiple 
comparisons test. Sham, N = 5; HSR N = 6; HSR + S1P, N = 5. 
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Figure 14. HSR Does Not Induce Apoptotic Signaling Activation in Mesenteric 
Microvessels 
Graphs show the quantifications of the band intensity from Western blots of proteins BAK, 
cytosolic cytochrome-c and fractin following Sham control treatment, HSR, or HSR + S1P. One-
way ANOVA with Tukey’s multiple comparisons test showed no significant difference in the 
expression levels of these proteins between all treatment groups. The data represent N = 3 or 4 
pooled samples of microvessels isolated from 7 - 10 for each group.  
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Figure 15. S1P rescues endothelial barrier dysfunction induced by inhibition of 
mitochondrial complex III. 
A. Dynamic changes in TER of RIMEC monolayers treated with vehicle control (bECM) followed 
by vehicle (VEH + VEH), antimycin-a followed by vehicle (AA + VEH) and AA followed by S1P 
(AA + S1P). RIMEC treated with antimycin-A (AA) display a time-dependent decrease in TER, 
which is rescued by treatment with S1P (N = 5 independent experiments for, with 4 - 8 monolayers 
per group in each experiment). B. Dynamic changes in TER of RIMEC treated with vehicle 
followed by vehicle, CCCP followed by vehicle (CCCP + VEH) and CCCP followed by S1P (CCCP 
+ S1P). Treatment with CCCP causes a time-dependent decrease in TER, which was not rescued 
by S1P treatment (N = 4 independent experiments, 4 - 8 monolayers per group in each 
experiment). Tracings indicate the mean resistance normalized to t = 0 (indicated by arrow) ± S.E. 
for each hour following treatment. Statistical analysis of normalized TER was done with repeated-
measures ANOVA, with Tukey’s multiple comparisons test, *P < 0.05. 
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Figure 16. Mitochondrial membrane disruption does not involve endothelial cell death. 
A. Representative WES showing cytosolic cytochrome-c in RIMECs treated with vehicle followed 
by vehicle (V/V), antimycin-a followed by vehicle or S1P (A/V, A/S), or CCCP followed by vehicle 
or S1P (C/V, C/S). B. Quantification of cytochrome-c cytosolic levels from 3 independent 
experiments (one-way ANOVA). C. Representative Propidium iodide (PI) stain images of RIMECs 
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treated with vehicle control, antimycin-a (AA) or CCCP. The number of PI-positive cells does not 
increase upon AA or CCCP treatment. D. Quantification of PI stained cells show no significant 
change in cell viability (one-way ANOVA). N = 5 independent experiments. 
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Figure 17. S1P Rescues Paracellular Junctional Disorganization Induced by Mitochondrial 
Complex III Inhibition 
Z-projection confocal immunofluorescence microscopy images of AJ and TJ proteins β-catenin 
and ZO-1 are shown. Vehicle treated control cells display continuous expression of junction 
proteins between endothelial cells (VEH + VEH). Inhibition of complex III with antimycin-a (AA) 
(AA + VEH) leads to gap formation (indicated by the arrows) and discontinuity in paracellular 
localization of junctional proteins. Treatment with S1P (added ~1 min after AA) maintains junction 
protein organization (AA + S1P). Images are representative of three separate experiments. 
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Figure 18. S1P rescues endothelial glycocalyx degradation induced by inhibition of 
mitochondrial complex III. 
A. Representative z-projections of confocal immunofluorescence images of the glycocalyx 
component heparan sulfate. High expression of heparan sulfate can be seen on RIMECs treated 
with vehicle only (VEH + VEH). Lower heparan sulfate fluorescence is seen in cells treated with 
AA + Vehicle. Cells treated with S1P show high heparan sulfate fluorescence (AA + S1P). B. 
Quantification of heparan sulfate fluorescence on RIMEC show a significant decrease induced by 
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AA that is rescued by S1P treatment.  Heparan sulfate expression is expressed as the mean 
integrated optical intensity (IOI) from three independent experiments. *P < 0.05, **P < 0.01 (one-
way ANOVA, Tukey’s multiple comparisons test). 
 
 74 
 
 
 
 
Figure 19. S1P protects endothelial cells from mitochondrial depolarization induced by 
inhibition of complex III. 
A. Representative confocal fluorescence images of JC-1-loaded RIMECs treated with antimycin-
a (AA) followed by S1P or vehicle. Control cells (VEH + VEH) show JC-1 aggregates (red 
fluorescence, indicated by arrows) in the mitochondria, indicating healthy mitochondria. Cells 
treated with AA show an increase in cytoplasmic JC-1 monomer (green fluorescence), indicating 
mitochondrial depolarization. Cells treated with S1P after antimycin-a (AA + S1P) show some 
intact mitochondria. B. Quantification of mitochondrial depolarization is shown in terms of 
Red/Green fluorescence ratio. AA treatment causes a significant decrease in red to green 
fluorescence compared to controls. AA treatment followed by S1P significantly increases red to 
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green fluorescence ratio on RIMECs, indicating protection of complex III by S1P. All images were 
acquired 10 minutes after addition of S1P or vehicle. **P < 0.01, ***P < 0.001 one-way ANOVA, 
followed by Tukey’s multiple comparisons test. Each dot represents the average of each 
independent experiment. N=4 experiments for each group, with at least four cells analyzed in 
each independent experiment.  
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Chapter Five: 
Overall Conclusions and Future Directions 
 
5.1 Overall Questions and Findings of this Dissertation 
Endothelial barrier dysfunction is a common feature of several vascular-related diseases, 
including hypertension, diabetes, traumatic injury, and cerebral diseases like stroke, 
subarachnoid hemorrhage and Alzheimer’s [144]. Understanding how different stimuli affect 
endothelial cell function is essential for the development of novel therapeutics for treatment of 
such diseases. With this in mind, in this study we have investigated the potential of S1P to rescue 
endothelial barrier function after challenge by different insults that produce hyperpermeability. 
Based on previous literature showing the detrimental effects of alcohol on the blood-brain barrier, 
and the barrier-enhancing properties of S1P, we hypothesized that S1P could ameliorate barrier 
dysfunction and junctional protein disruption caused by alcohol treatment in an in vitro model of 
blood-brain barrier. We found that alcohol elicits brain endothelial cell monolayer barrier 
dysfunction, confirming previous findings. We then showed that brain endothelial cell monolayer 
barrier disruption is accompanied by increased permeability to solutes of different sizes. This is 
accompanied by breakage of junction proteins thought to be determinants of endothelial barrier 
function in the central and peripheral circulation, thus having a role in blood-brain barrier 
homeostasis, such as Claudin-5, VE-cadherin, and β-catenin. We show that S1P is able to 
reverse the detrimental effects of alcohol in brain endothelial cell function and junctional integrity, 
confirming our hypothesis.  
We further investigated the barrier-protective effects of S1P during challenge with 
hemorrhagic shock and resuscitation in vivo. This model has clinical significance, as traumatic 
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injuries cause systemic microvascular hyperpermeability. We hypothesized that S1P could 
improve the microvascular barrier function during HSR by preserving paracellular junction 
integrity, preventing loss of glycocalyx on endothelial cells, and reducing inflammation. Our 
hypothesis was proven correct when administration of S1P in resuscitation fluids preserved the 
localization of adherens junctions between endothelial cells, attenuated thinning of the glycocalyx 
layer, and reduced the interaction between leukocytes and the endothelium. Due to increasing 
evidence that the mitochondria play a role as signaling molecules in the endothelium rather than 
an exclusively metabolic part, we investigated whether mitochondrial dysfunction could disrupt 
endothelial barrier, and whether S1P is able to reverse these effects by protecting mitochondrial 
function. We found that S1P was able to rescue mitochondrial dysfunction produced by HSR, 
suggesting that the mitochondria are important regulators of barrier function. Interestingly, we 
found that blockage of the mitochondrial complex III leads to endothelial barrier dysfunction, 
supported by breakage of junction proteins β-catenin and ZO-1, and shedding of glycocalyx 
component heparan sulfate. We also found that uncoupling of electron transport chain (ETC) also 
leads to endothelial barrier dysfunction. However, we unexpectedly found that S1P is only able to 
prevent barrier dysfunction when it is caused by complex III inhibition, and not by direct disruption 
of mitochondrial membrane potential with an ionophore, suggesting that S1P acts through a 
mechanism that involves or is downstream of complex III, but is not immediately affected by 
uncoupling of the proton gradient across the inner mitochondrial membrane. When testing the 
mechanisms of S1P-induced barrier protection, we confirmed our hypothesis and showed that 
S1P at least partly protects mitochondrial function by preventing depolarization as a result of 
complex III inhibition.  
Collectively, these data support our overall hypothesis that S1P can protect endothelial 
barrier during alcohol intoxication and hemorrhagic shock by preserving the integrity of junction 
proteins and the glycocalyx, and protecting mitochondrial function. 
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5.2 Future Directions 
Our results suggest that alcohol intoxication could exacerbate the effects of a secondary 
inflammatory insult in the endothelial barrier. One immediate future direction as a result of this 
work is to study the effects of alcohol on the BBB in vivo, in the presence of secondary stimuli 
such as traumatic brain injury, as well as the potential therapeutic effect of S1P. In a previous 
investigation we observed that S1P confers a beneficial effect to the mesenteric microcirculation 
when HSR is combined with acute alcohol intoxication [44]. Under such conditions, alcohol 
appears to act by causing additional insult to the endothelial barrier. Investigation of this model in 
the BBB would likely expand the scope of possible therapeutic applications for S1P. The signaling 
mechanisms underlying S1P’s protection under a “two-hit” scenario can also be subject of future 
investigation. Our data suggest that some common mechanisms probably underlie the ability of 
S1P to enhance the endothelial barrier whether hyperpermeability is caused by HSR or alcohol. 
For example, paracellular junction integrity would likely be further disrupted with alcohol treatment 
preceding HSR. On the other hand, the effects of alcohol on the endothelial glycocalyx have been 
largely understudied, making it harder to predict the outcomes. However, the development of 
techniques for glycocalyx visualization suggest that alcohol promotes a considerable collapse of 
this structure [145], providing a foundation for future investigation.  
Another important future direction of this study is to investigate the molecular mechanism 
that explains how mitochondrial function contributes to the integrity of intercellular junctions and 
endothelial glycocalyx. We have provided insight by showing involvement of the mitochondrial 
complex III in barrier function and S1P-mediated barrier enhancement. However, the specific 
molecular mechanisms that link the complex III to junctional and glycocalyx integrity are not 
known. The possible involvement of complex III-generated mitochondrial ROS and disturbances 
in calcium homeostasis may be subject of future studies. Furthermore, future studies on whether 
the mitochondria is involved in alcohol-induced barrier dysfunction may provide additional 
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information on how to enhance the function of endothelial cells during inflammatory challenges 
that involve alcohol intoxication. 
  
 In summary, our findings present the first evidence that S1P can rescue the functional and 
morphological integrity of endothelial cells disrupted by alcohol. In addition, we provide the first 
demonstration that S1P can protect against HSR-induced endothelial mitochondrial membrane 
disruption in combination with endothelial junctional and glycocalyx damage, increased leukocyte 
rolling and adhesion, and microvascular leakage. Our findings provide new insights on the 
therapeutic potential of S1P, and the importance of endothelial mitochondrial function as a 
potential pharmacologic target for future interventions. We expect that future work will produce 
additional advances that may lead to improved therapeutics to prevent excessive microvascular 
leakage in inflammatory disease conditions.  
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